Prognostic Significance of Cell-Matrix Interactions in Epithelial Ovarian Cancer (Syöpäsolujen ja soluväliaineen välisten tekijöiden ennusteellinen merkitys epiteliaalisessa munasarjasyövässä) by Sillanpää, Sari
Doctoral dissertation
To be presented by permission of the Faculty of Medicine of the University of Kuopio
for public examination in Auditorium, Mediteknia building, University of Kuopio,
on Friday 5th October 2007, at 12 noon
Institute of Clinical Medicine,
Pathology and Forensic Medicine,
Gynaecology and Obstetrics
Institute of Biomedicine, Anatomy
University of Kuopio and Kuopio University Hospital
SARI SILLANPÄÄ
Prognostic Significance of Cell-Matrix 
Interactions in Epithelial Ovarian Cancer
JOKA
KUOPIO 2007
KUOPION YLIOPISTON JULKAISUJA D. LÄÄKETIEDE 416
KUOPIO UNIVERSITY PUBLICATIONS D. MEDICAL SCIENCES 416
Distributor :   Kuopio University Library
   P.O. Box 1627
   FI-70211 KUOPIO
   FINLAND
   Tel. +358 17 163 430
   Fax +358 17 163 410
   www.uku.fi/kirjasto/julkaisutoiminta/julkmyyn.html
Series Editors:   Professor Esko Alhava, M.D., Ph.D.
   Institute of Clinical Medicine, Department of Surgery
   
   Professor Raimo Sulkava, M.D., Ph.D.
   School of Public Health and Clinical Nutrition
   
   Professor Markku Tammi, M.D., Ph.D.
   Institute of Biomedicine, Department of Anatomy
Author´s address:  Institute of Clinical Medicine, Pathology and Forensic Medicine
   University of Kuopio
   P.O. Box 1627
   FI-70211 KUOPIO
   FINLAND
   Tel. +358 17 162 742
   Fax +358 17 162 753 
Supervisors:   Professor Veli-Matti Kosma, M.D., Ph.D.  
   Institute of Clinical Medicine, Pathology and Forensic Medicine  
   University of Kuopio and Kuopio University Hospital  
   Gynegologist Maarit Antti la, M.D., Ph.D.  
   Department of Gynecology and Obstetrics  
   Kuopio University Hospital  
   Professor Markku Tammi, M.D., Ph.D.  
   Institute of Biomedicine, Department of Anatomy  
   University of Kuopio  
   Professor Seppo Saarikoski, M.D., Ph.D.  
   Department of  Gynecology and Obstetrics  
   Kuopio University Hospital
Reviewers:   Docent Seija Grénman, M.D., Ph.D.  
   Department of Obstetrics and Gynaecology
   Turku University Hospital   
   Docent Helena Autio-Harmainen, M.D., Ph.D. 
   Department of Pathology
   Oulu University Hospital
Opponent:   Professor Frej Stenbäck, M.D., Ph.D.   
   Department of Pathology   
   University of Oulu 
ISBN 978-951-27-0676-1
ISBN 978-951-27-0753-9 (PDF)
ISSN 1235-0303
Kopijyvä
Kuopio 2007
Finland
  
Sillanpää, Sari. Prognostic significance of cell-matrix interactions in epithelial ovarian cancer. 
Kuopio University Publications D. Medical Sciences 416. 2007. 97 p.  
ISBN 978-951-27-0676-1 
ISBN 978-951-27-0753-9 (PDF) 
ISSN 1235-0303 
 
ABSTRACT 
   In global terms, ovarian cancer was the sixth most common cancer of women in 2004. In 
Finland 486 new ovarian cancer cases were diagnosed in the year 2004 and 302 deaths due to 
ovarian cancer were observed during that year, i.e.ovarian cancer is responsible for most 
gynaecological cancer deaths. Epithelial ovarian cancer patients have a poor prognosis because 
most of the cases are detected at an advanced stage.  
   In this retrospective study, the expression and prognostic significance of factors  related to the 
cell-matrix interaction (CD44, MMP-2,-7 and –9, and EMMPRIN) were studied, and their 
relation to clinicopathologiacal factors and previously studied cell adhesion markers (β-catenin 
and hyaluronan) were evaluated. The study series consisted of 307 epithelial ovarian cancer 
patients treated in Kuopio University Hospital and Jyväskylä Central Hospital, Finland between 
1976 and 1992 and subsequently followed-up until January 2004. Immunohistochemical 
analyses were used to examine the expression of these biological markers. 
Cancer cells of the epithelial ovarian malignancies expressed membranous CD44, cytoplasmic 
MMP-2, -7, -9 and membranous EMMPRIN with mean percentages of 20%, 38%, 46%, 87% 
and 20% respectively. The expressions of cancer cell-associated CD44, MMP-2, -7 and -9 and 
membranous EMMPRIN were significantly related to other clinicopathological factors 
indicative of better survival (low grade of the tumor, non-serous histological subtype, low stage 
of the tumor and small or no residual tumor). In contrast, stromal expression of MMP-9 and 
EMMPRIN were associated with advanced stage tumors. The presence of nuclear β-catenin, 
especially in endometrioid tumors, was shown to associate with MMP-7 and CD44 expression 
in cancer cells. In tumor stroma, MMP-2 and –9 expressions were found to be associated with 
hyaluronan expression. 
In univariate analyses, all the studied markers (CD44, MMP-2, -7, -9 and EMMPRIN) while 
present in cancer cells were found to be predictors of better disease related survival (DRS). In 
addition, CD44, MMP-2 and –7 were also found to be predictors of better recurrence-free 
survival (RFS). Stromal MMP-9 was found to be associated with poor DRS, while stromal 
MMP-7 correlated with poor RFS in the univariate analyses.  In multivariate analyses, intense 
MMP-7, strong MMP-2 and CD44 on cancer cells were found to be independent predictors of 
better survival in epithelial ovarian cancer. The conventional prognostic factors such as FIGO 
stage, histological type and grade, residual tumor and adjuvant chemotherapy were found to be 
independent predictors of survival in these epithelial ovarian cancer patients as well. 
The results show that cancer cell associated MMP-2 and –7, and CD44, along with the 
conventional clinicopathological factors, do have a prognostic impact in epithelial ovarian 
cancer. The role of MMPs in tumor progression seems to depend on tissue location, i.e. they can 
act against tumor advancement when present in the tumor epithelium but can promote tumor 
progression while in the stroma. 
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1. INTRODUCTION 
     In global terms, ovarian cancer was the sixth most common cancer of women in 
2004 [1]. In Finland 486 new ovarian cancer cases were diagnosed in year 2004 and 
there were 302 deaths due to ovarian cancer during that year. Thus ovarian cancer was 
the most common cause of gynaecological cancer deaths [2]. Age-adjusted incidence 
rate of ovarian cancer in Finland was 10.2 per 100,000 people [2]. Epithelial ovarian 
cancer patients have a poor prognosis, because most of the cases are found at an 
advanced stage [3-5]. It is clear that prognosis would be much better if the disease 
would be diagnosed at an earlier stage [5], because effective treatment choices are 
available for these patients. In addition, the diagnosis is difficult to make, because 
patients may be symptomless. Even when in an advanced form, the disease may evoke 
only non-specific symptoms [6].  
The pathogenesis of the disease is still unknown, but it has been thought that ovarian 
epithelial cancer arises from the surface epithelium or surface epithelial inclusion glands 
[7-9]. Two distinct pathways of ovarian carcinogenesis have been found, a slow 
development through a benign neoplasm and a more aggressive, de novo genesis of 
cancer [10]. Epithelial ovarian cancer is thought to disseminate by exfoliation of tumor 
cells, which spread around the peritoneal cavity and in its later stages also metastasize 
to distant sites [11-13]. Tumor cells may also pass through the lymph vessels in the 
diaphragm and spread to pleura [6][12-13] or directly invade nearby structures [12-13]. 
A more detailed, molecular knowledge of the spread mechanisms of ovarian cancer is 
essential if one wishes to make a more accurate estimate of patient survival. In addition, 
understanding the factors that affect the spread of tumor may be the key to the 
identification of new therapeutical targets. 
Several events must occur if ovarian cancer is to metastasize. Firstly, cancer cells have 
to loosen their E-cadherin-dependent adhesion [14], this being followed by cancer cell 
attachment to the extracellular matrix. This process is mediated through different 
adhesion molecules, for example CD44, cadherins, catenins and integrins [11][14]. 
Matrix metalloproteinases (MMPs) can influence cell adhesion by processing these 
different adhesion molecules [15]. Integrins play an important role, during the cancer 
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cell migration through the interstitial matrices, by providing anchorage and activating 
pro-migratory signals [14]. The migration of ovarian cancer cells towards extracellular 
matrix has been shown to be regulated by the interaction between CD44 and hyaluronan 
(HA) [16]. CD44 can also bind to MMP-9 on cell surface, allowing MMP-9 to promote 
tumor invasion and to stimulate angiogenesis [17]. Secondly, cancer cells have to 
penetrate through the basement membrane and the surrounding extracellular matrix to 
be able to grow further [11]. MMPs are able to cleave all major types of structural 
components of the basement membranes [18-19]. Regulation of apoptosis has an 
important role, during tumor growth. CD44 can inhibit apoptosis [20] whereas MMP-7 
can both trigger and inhibit this kind of programmed cell death [15][17]. In vitro studies 
have suggested that CD44 mediates binding of ovarian cancer cells to HA on the 
peritoneal mesothelium [21-22].  
In the present study, the expression and prognostic value of factors related to cell 
adhesion and cell-matrix interactions (CD44, MMP-2,-7 and –9, EMMPRIN) were 
studied by immunohistochemistry on archived tissues of epithelial ovarian cancers. In 
addition, their relation to previously studied cell adhesion factors (HA and β-catenin) 
were investigated. 
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2. REVIEW OF THE LITERATURE 
2.1 Epidemiology of epithelial ovarian cancer 
   Ovarian cancer was the sixth most common cancer (204 499 cases) and the seventh 
most common cause of cancer deaths (124 860 deaths) in women globally during the 
year 2004 [1].  In the European Union, an estimated 42 700 new cases were diagnosed 
and 28 300 deaths were recorded. Thus, ovarian cancer is the 5th most common cause of 
cancer deaths in women [23]. Age-adjusted incidence rate of ovarian cancer in Finland 
was 10.2 per 100,000 people, 484 new ovarian cancer cases and 302 deaths were 
attributed to ovarian cancer in the year 2004 [2]. Ovarian cancer was thus the fifth most 
common cause of cancer death in women in Finland [2]. The incidence of ovarian 
cancer is highest in the developed areas of the world [1]. It has been noted that 
incidence rates and mortality rates are decreasing in some northern European countries 
mainly in younger patients; however in some southern European countries the rates 
continue to increase [24]. The fact that ovarian cancer seems to be declining in the 
younger age group could be partly explained by the fact that use of oral contraceptives 
has taken place earlier, and to a larger extent, in northern Europe. The upward trend in 
mortality and incidence in epithelial ovarian cancer in southern European countries has 
been explained partly by decreasing parity in these populations during the follow-up 
times ranging from the 1950s until current time [24]. Also, problems of diagnosis, 
treatment and lifestyle habits could explain some of these differences [24]. In the older 
female populations, the incidence of epithelial ovarian cancer is predicted to double by 
2030 in comparison to the 1990 values [25]. 
2.2 Etiology of epithelial ovarian cancer 
   The exact etiology of epithelial ovarian cancer, and the cell of origin, is still unknown. 
The best supported theory postulates that epithelial ovarian cancer arises from ovarian 
surface epithelium or surface epithelial inclusion glands, although also other 
possibilities are still considered [7-10]. 
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Four different hypotheses based on epidemiological studies have been proposed to 
possibly account for the development of epithelial ovarian cancer [10]. The first theory, 
“incessant ovulation” claims that the risk of ovarian cancer increases during each 
ovulation, because the traumatized epithelium of ruptured follicles is continuously 
repaired [10][26] and the rapid proliferation of surface epithelial cells during this repair 
exposes cells to malignant transformation [27]. There are some epidemiological data 
concerning risk factors for epithelial ovarian cancer to support this hypothesis [28-29]. 
The second theory, “Gonadotrophin hypothesis”, suggests that high levels of pituitary 
gonadotrophins increase cancer risk by stimulating the ovarian surface epithelium [10]. 
This theory is supported by the fact that both pregnancy and the oral contraceptive pills 
decrease human gonadotropin levels [30]. The third theory, hormonal hypothesis, 
proposes that an excess of androgen stimulation increases the risk, whereas 
progesterone has a protective effect against epithelial ovarian cancer [10][30]. Ovarian 
cancer risk has been found to be increased by 2.5-fold in women with polycystic 
ovarian syndrome; the key characteristics of these patients are increased androgen 
levels, a concept which supports the above theory [31]. The fourth theory, the 
inflammation hypothesis, suggests that genital tract infections and the subsequent 
inflammation may be related to ovarian cancer development [32]. This theory is 
supported by findings that the risk of epithelial ovarian cancer is decreased in women 
who use consistently aspirin or non-steroidal anti-inflammatory agents for any reason 
[33-34]. None of the four hypotheses, even though all have their own supporting 
findings, have been able to explain all the aspects known about ovarian carcinogenesis 
[10].  
Today it has been acknowledged that epithelial ovarian cancer is a heterogeneous 
disease [10]. Morphologically, epithelial ovarian cancers are assigned into different 
categories; serous, mucinous, endometrioid, clear cell, transitional, squamous, mixed 
and undifferentiated type [7-8]. The tumors in each category are further subdivided into 
three groups; benign, borderline and malignant, to reflect their behavior [35]. The 
different morphological subtypes may have different pathways of carcinogenesis. 
Recent data suggest that there are two distinct pathways in ovarian tumorigenesis; 
mucinous, clear cell, low grade serous, and endometrioid cancers develop through a 
 17 
 
well-defined adenoma-carcinoma sequence, while the more common high grade serous 
and endometrioid cancers develop de novo from the  ovarian surface epithelium or 
surface epithelial inclusion cysts [7][35-36]. It has been shown that each of these 
histological subtypes is associated with distinct morphologic and molecular genetic 
alterations. (Table 1) 
 
Table 1. Precursors and molecular genetic alterations of ovarian tumors, adapted from 
Shih et al. [35], Bell [7] and Tavassoli et al.[37]. 
Tumor Precursors Genetic alterations 
Low grade  
serous carcinoma 
 
Serous 
cystadenoma/adenofibroma 
Borderline tumor 
BRAF and KRAS mutations 
Mucinous carcinoma 
 
Mucinous cystadenoma 
Borderline tumor 
KRAS mutations 
 
Low grade  
endometrioid carcinoma  
 
 
Endometriosis 
Endometrioid adenofibroma 
Borderline tumor 
 
KRAS mutations and β-catenin 
mutations 
Microsatellite instability 
LOH or mutations in PTEN 
Clear cell carcinoma 
 
Endometrioisis 
Borderline tumor 
KRAS and Microsatellite instablity 
TGF-betaRII mutation 
High grade  
serous carcinoma 
 
Not identified 
 
 
 
p53 mutations 
Amplification and overexpression of 
HER2/neu gene and AKT2(protein 
kinase B) gene 
inactivation of p16 gene 
Dysfunction of BRCA1 and/or BRCA2 
High grade endometrioid 
carcinoma 
Not identified 
 
p53 mutations 
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2.3 Risk factors for ovarian cancer 
   Risk factors for ovarian cancer are much less clear than those of other genital tumors. 
Known factors for a decreasing risk of ovarian cancer are use of oral contraceptives, 
number of pregnancies and lactation [5][38]. The use of oral contraceptives is the best 
documented factor having any protective significance. Its significance has been studied 
in 12 case-control studies totalling 2197 patients with ovarian cancer [28]. It has also 
been noted that the longer the use of oral contraceptives, the better the benefit [5][38]. A 
prospective cohort study of 121,700 female registered nurses aged 30-55 years, showed 
a statistically significant inverse association between parity and risk of ovarian cancer 
[29], with each additional term pregnancy reducing the risk [28]. It has also been 
documented that breast feeding associates with decreased risk of ovarian cancer [28]. 
Recently, it was found that moderate nonoccupational physical activity correlates with a 
decreased risk of ovarian cancer [39]. 
Factors previously shown to increase the risk of ovarian cancer are; age, ovulation, 
family history, null parity, poly-cystic ovary disease, pelvic inflammatory disease and 
high-fat diet [28]. Age and family history are the best documented risk factors. 
Advancing age is a significant risk factor for the development of ovarian cancer. The 
risk has been reported to increase from 15.7 to 54 per 100,000 between the ages of 40 to 
79 years [40]. Mutations in the BRCA1 and BRCA2 genes dramatically increase the 
risk of ovarian cancer [41]. Approximately 5-10% of the ovarian cancer cases can be 
traced to an inherited susceptibility [42]. The estimated risk of ovarian cancer in 
BRCA1 mutation carriers is 30% to 50% by the age 60 years [43-45]. Early menarche 
and late menopause have also been reported to slightly increase the risk of this disease 
[4][46]. It has been also reported that the number of ovulations occurring in time frame 
the 20-29 years of age are associated with an increased risk [47]. The ovarian cancer 
risk is higher among women with polycystic ovarian syndrome [31]. Obesity has been 
associated with the risk of ovarian cancer and a risk was shown to rise modestly with 
increasing body mass index [48-49]. 
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2.4 Diagnosis and management of epithelial ovarian cancer 
   Ovarian cancer is difficult to diagnose at an early stage of the disease and most of the 
cases are found at an advanced stage, mainly due to the  symptomless period in the early 
phases of the disease [3-5] and poor screening tests [3-4]. The survival rate of epithelial 
ovarian cancer increases dramatically if the disease is diagnosed at an early stage [5]. 
The diagnosis of ovarian cancer is based on histological samples obtained at surgery. 
Preoperatively, it is possible to assay serum CA-125 level, and perform transvaginal 
ultrasound and pelvic examinations [3-4]. The risk of malignancy index (RMI), as based 
on a serum CA125 level, ultrasound findings and menopausal status, has been shown to 
be able to discriminate rather accurately between malignant and benign pelvic masses 
[50]. However, none of these can reliably diagnose ovarian cancer; and therefore a 
biopsy optained in laparoscopy or laparotomy is needed for definite diagnosis [4]. 
   Surgery is the most important treatment for ovarian cancer patients, and the decision 
of treatment strategy is also based on the findings obtained in surgery. During the 
surgery adequate staging and maximal cytoreduction should be done [3-4]. In an early 
invasive disease, all patients should be fully staged during laparotomy according to the 
guidelines of FIGO and the European Organisation for Research and Treatment of 
Cancer [51][52]. Lymph node assessements have been shown to be especially important 
in the staging of early ovarian cancer to avoid understaging and potentially suboptimal 
treatment [53]. In advanced stage cancers, surgery should involve a total abdominal 
hysterectomy, bilateral salpingo-oophorectomy and infracolic omentectomy, and 
lymphadenectomy if all of the tumor is being debulked [3][5][51]. Removing the 
primary tumor mass to the gratest extent possible should be done, because the size of 
the residual tumor is one of the most powerful prognostic factors of patient survival 
[3][5][51]. If the patient wishes to preserve fertility, stage IA G1 cancers can be 
managed conservatively with unilateral salpingo-oophorectomy [3][5]. Kumpulainen 
and co-workers have reported that operative treatment of ovarian cancer could be 
improved by the centralisation of primary surgery to large hospitals with physicians 
specialised in ovarian cancer surgery [53] 
With the exception of patients with stage IA G1 disease, all other patients with 
epithelial ovarian cancer are recommended to be treated with chemotherapy [3][54-55]. 
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Chemotherapy is started as soon as patients have recovered from the surgery [3]. A 
platinum-taxane combination being used as the first line chemotherapy [3]. Several 
drugs are also under evaluation for first-line treatment; Docetaxel, Irinotecan, 
Gemcitabine, Pegylated liposomal doxorubicin and Topotecan [54]. All patients with 
clear cell carcinomas are treated with chemotherapy, because of their poor survival 
prognosis [3]. Patients to whom combination therapy is considered to be too hars are 
treated with carboplatin only [3]. Radiation therapy was employed for over 50 years as 
an adjuvant to surgery in the management of ovarian cancer. Recent results have shown 
that radiotherapy can improve progression-free survival, but only in those patients who 
had complete remission after primary cytoreductive surgery and induction 
chemotherapy. However, treatment-related side effects are frequent and limit the use of 
radiotherapy [56].  Despite the fact that 70-80% of the patients achieve a good initial 
response to the first-line chemotherapy, disease will relapse in most of the patients 
[3][5]. In their review, Guppy and co-workers concluded that relapsed ovarian cancer is 
incurable and the main objectives for the treatment of these patients should be relief of 
symptoms and improvements in the quality of life [5]. 
 
2.5 Traditional clinicopathological prognostic factors in 
epithelial ovarian cancer 
2.5.1 Age 
   The age of the patient correlates with the outcome of the ovarian cancer [57-58]. The 
median age of patients at diagnosis has ranged from 53 to 63 years [25][57]. The 
incidence of this disease increases with increasing age and is very low for women under 
30 years [25]. It has been proposed that elderly patients have a significantly shorter 
survival expectancy as compared to younger patients with this malignancy [58-61]. One 
reason for this finding could be that older women are more likely to be diagnosed with 
more advanced disease [25][53]. Older women with ovarian cancer are treated less 
aggressively than their younger counterparts [53][58]. Well-differentiated lesions also 
seem to be more common in younger patients [62], and more frequent gynaecological 
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examinations during the childbearing age may favor an earlier detection in younger 
patients [62]. Villa et al have reported that patients 53 years old or less with stage I-II 
ovarian cancer tend to have a better 5-year survival rate than older patients with the 
same stage [63]. For stage III-IV disease, women under 45 years of age exhibited a 
significantly better 5-year relative survival rate compared to women over 85 years of 
age [58]. However, some studies have indicated that age has no effect on survival [64-
67].  
2.5.2 Stage 
   Ovarian cancer is a surgically staged disease and most ovarian cancers are approached 
operatively unless a significant medical contraindication to the procedure exists. 
Ovarian carcinoma is staged according to the International Federation of Gynecology 
and Obstetrics (FIGO) standards and with the classification based on findings at clinical 
examination and surgical exploration [4]. The staging system is described in Table 2. 
FIGO stage is the only factor influencing treatment decisions at the initial diagnosis. 
FIGO stage is a well recognized prognostic factor of great importance in epithelial 
ovarian cancer [60-61][66][68-70].  
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Table 2. FIGO staging system of Ovarian Cancer and survival percentages according to 
FIGO staging of ovarian cancer [57][71] 
FIGO stage 
5-Year 
Survival 
Stage I Tumor limited to the ovaries (one or both) 60-90% 
Stage IA 
 
Tumor limited to the ovary; capsule intact, no tumor on ovarian 
surface. No malignant cells in ascites or peritoneal washings.  
Stage IB 
 
 
Tumor limited to both ovaries; capsule intact, no tumor on the 
ovarian surface; no malignant cells in ascites or peritoneal 
washings.  
Stage IC 
 
 
Tumor limited to one or both ovaries with any of the following: 
capsule ruptured, tumor on ovarian surface, malignant cells in 
ascites or peritoneal washings. 
 
Stage II Tumor involves one or both ovaries with pelvic extension 37-66% 
Stage IIA 
 
Extension and/or implants on uterus and/or tube(s). No malignant 
cells in ascites or peritoneal washings.  
Stage IIB 
 
Extension to other pelvic tissues. No malignant cells in ascites or 
peritoneal washings.  
Stage IIC 
 
Pelvic extension (2a or 2b) with malignant cells in ascites or 
peritoneal washings.  
Stage III 
 
 
Tumor involves one or both ovaries with microscopically 
confirmed peritoneal metastasis outside the pelvis and/or regional 
lymph node metastasis. 
5-50% 
 
 
Stage IIIA Microscopic peritoneal metastasis beyond pelvis  
Stage IIIB 
 
Microscopic peritoneal metastasis beyond pelvis, 2cm or less in 
greatest dimension  
Stage IIIC 
 
Peritoneal metastases beyond pelvis more than 2cm in greatest 
dimension and/or regional lymph node metastasis  
Stage IV Distant metastasis (excluding peritoneal metastasis) 0-17% 
2.5.3 Residual tumor 
   The volume of residual tumor remaining after primary surgery has been found to be 
an important prognostic factor in epithelial ovarian cancer [57]. This was initially found 
by Griffiths, who defined optimal cytoreductive surgery in the treatment of ovarian 
cancer [72]. The size of the optimal cytoreduction has been described to be less than 1.5 
to 2 cm in diameter, however it has been noted that the patients with a residual tumor 
less than 0.5 cm or no residual at all have an even better outcome [57], the current 
definition of optimal cytoreduction is no macroscopic tumor [3]. Van der Burg and co-
workers found that patients who underwent debulking surgery after primary surgery and 
chemotherapy, had a significantly longer progression-free and overall survival 
compared to those who did not go through the second operation [73]. Kumpulainen and 
co-workers have shown that the percentage of patients with no macroscopic tumors 
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increased most extensively after cytoreductive surgery when operated by a specialist 
gynaecologic oncologist [53]. The absence of tumor bulk has been found to be an 
independent predictor of a better survival in several studies [61][64-67][69]. Residual 
tumor is thus one of the most important prognostic factors in epithelial ovarian cancer.  
2.5.4 Histological subtype 
Table 3. WHO histological classification of epithelial ovarian tumors [37][74] 
  
Common Epithelial-Stromal Tumors 
Serous tumors 
      benign 
      borderline 
      malignant 
Mucinous tumors 
      benign 
      borderline 
      malignant 
      mucinous cystic tumor with mural nodules 
      mucinous cystic tumor with pseudomyxoma peritonei 
Endometrioid tumors 
      benign 
      borderline 
      malignant 
Clear cell tumors 
      benign 
      borderline 
      malignant 
Transitional cell tumors 
      benign 
      borderline 
      malignant 
Mixed epithelial tumors 
      benign 
      borderline 
      malignant 
Undifferentiated carcinoma 
Unclassified epithelial tumors 
 
   Histopathologically, epithelial ovarian cancers are classified as shown in Table 3. In 
undifferentiated carcinomas, the epithelial structure is too poorly differentiated to be 
placed in any of the groups [51]. It is important to define the subtype, because 
differences in their biological behavior affect the likelihood of spreading, and thus the 
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prognosis [57]. The frequency and prognosis of these subtypes are shown in Table 4. 
Histological subtypes, except for the clear cell subtype, have not been proven to have 
any independent value in predicting survival of the patients and should not impact on 
treatment decision making [57]. 
 
Table 4. Frequencies of the different histological subtypes and their survival rates 
[3][57][75-76]  
Subtype Frequency   %        5-year survival 
  
  
Friedlander
 
      
Cotran 
Current Care 
guidelines 
  FIGO 
  annual 
  report 
                      
Friedlander
 
      FIGO 
      annual 
      report 
Serous 30-70 40 53 51 20-35 36.9 
Endometrioid 10-20 20 14 18 40-60 59.6 
Mucinous 5-20 10 16 12 40-60 62.8 
Clear cell 3-10 6 6 8 35-50 58.8 
Undifferentiated 1 10 6 7 15-20 37.2 
Mixed     5 4   57.4 
 
2.5.5 Histological grade 
   Histopathologically, epithelial ovarian cancers are graded, based on the WHO 
classification as, follows: grade cannot be assessed, well differentiated, moderately 
differentiated and poorly differentiated [51]. The frequencies and survival percentages 
according to the WHO grading of ovarian cancer are shown in Table 5. Recently, 
Silverberg proposed a new histopathologic grading system for ovarian carcinoma, based 
on predominant architectural pattern and cytologic atypia [77]. The prognostic 
significance of grading based on WHO classification in ovarian cancer has been studied 
previously and it has been noted that grading is a significant predictor of survival 
[61][66-67][70-71]. However, it seems that histological grade is a more significant 
predictor in low stages than in high stages of ovarian cancer [63][65][70]. 
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Table 5. Frequencies and survival percentages according to WHO grading of ovarian 
cancer [57][71] 
Grade Frequency % 5-Year Survival 
Well differentiated 10 70-80 
Moderately differentiated 25 30-45 
Poorly differentiated 65 5-25 
 
2.6 Prognostic factors related to cell-matrix interactions, 
invasion and metastasis 
2.6.1 Extracellular matrix 
    The stroma surrounding tumor cells provides the connective tissue framework for the 
tumor tissue. This framework is composed of extracellular matrix (ECM) as well as 
cellular components such as fibroblasts, immune and inflammatory cells, blood vessels 
and fat cells [78]. ECM is secreted locally and forms a major proportion of the volume 
of any connective tissue; it can be divided into the basement membrane and the 
intersitial connective tissue [75]. Interstitial connective tissue is present in the spaces 
between epithelial, endothelial and smooth muscle cells and the basement membrane 
separates epithelial and stromal tissue [75]. Three different groups of molecules form 
both of these ECM components: fibrous structural proteins, including collagens and 
elastins; adhesive glycoproteins, such as laminin and fibronectin [75][79]; and 
proteoglycans and glycosaminoglycans like hyaluronan [75]. ECM provides 
architectural structure and strength for cellular communication, adhesion and migration 
[78].  
Malignant tumor cells differ from benign neoplastic cells in having the capacity to 
infiltrate, invade and metastasize to distant sites. The interaction between the ECM and 
malignant cells is necessary at several stages in this metastatic cascade  [75]. Stromal 
host cells and malignant cells alter ECM by producing stroma-modulating growth 
factors, proteases and protease inhibitors, generating a permissive and supportive 
environment for tumor progression [78][80].  These factors can act in both paracrine 
and autocrine manners, initiating the secretion of specific pro-migratory and –invasive 
components and their receptors, and reducing the expression of protease inhibitors [78]. 
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The imbalance between proteases and their inhibitors leads to degradation of ECM 
components, resulting in growth factor release and the generation of reactive ECM 
fragments [78]. Together these tumor and ECM derived growth factors induce 
angiogenesis [81-82] and also activate inflammatory cells [82] and fibroblasts [83]. 
These active fibroblasts secrete proteases (including matrix metalloproteinases) and 
growth factors that change the properties of the stroma, which then promotes malignant 
tumor growth [78][83-84]. Also active inflammatory cells, mainly macrophages, can 
relase at least one matrix metalloproteinase (MMP-9) which then contributes to 
angiogenesis, cell growth, and the formation of ascites fluid, as shown with human 
ovarian cancers in nude mice [85]. Thus ECM controls the behavior of cells, often 
through signals mediated by integrins, a family of cell-surface adhesion receptors [14]. 
Integrins determine whether cells proliferate and migrate in response to these different 
soluble growth factors and cytokines [14]. It seems that ECM is not only a barrier 
between epithelial cells, but also an active contributor, stimulating or suppressing the 
malignant behavior of cancer cells.  
 
Figure 1. Illustration of the sequence of event in the invasion of epithelial basement membranes 
by tumor cells. Loss of cadherins plays a key role in the onset of this process, by loosening 
intercellular adhesion. Integrins carry out an essential role during cell migration. Proteases lead 
to degradation of ECM components, including collagen IV. The interaction between hyaluronan 
and CD44 regulates important functions during tumorigenesis, and it can promote invasion also 
by regulating production, activation and cell-surface presentations of MMPs. Modified from 
Cotran and co-workers [75]. 
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2.6.2 Hyaluronan 
    Hyluronan (HA, hyaluronic acid, hyaluronate) is a polysaccharide, which belongs to 
the family of glycosaminoglycans. HA is a huge molecule, which consists of repeats of 
a simple disaccharide composed of glucuronic acid and N-acetyl-glucosamine [75]. HA 
is synthesized as an unmodified polysaccharide by one of three hyaluronan synthases, -
HAS1, HAS2 or HAS3. After synthesis, HA is extruded through the plasma membrane, 
either remaining on cell surface, or extending or diffusing into ECM [86].  
HA is involved in a variety of physiological and pathological processes [87-89], 
including tissue development and remodelling, and cancer progression [86]. HA works 
as a ligand for proteoglycans such as aggrecan and versican and functions as the 
backbone for large proteoglycan complexes [75]. Its ability to form interactions with 
proteoglycans and other extracellular macromolecules, maintains the space between the 
cells [86]. A high concentration of HA expands the tissue extracellular space, deforming 
the normally compact architecture of ECM, a change that facilitates invasion [90].  HA 
can also interact with many cell surface receptors, such as CD44 [75]. The interaction 
between HA and CD44 regulates many important cellular functions during 
tumorigenesis, like cell-survival and ERBB-family signaling [86]. HA can promote 
invasion also by regulating the production, activation and cell-surface presentations of 
MMPs [91-94].  
It has been noted that HA is usually expressed in higher quantities in malignant 
tumors than in the corresponding normal tissues as well as in benign masses [95]. HA is 
produced either by the cancer cells themselves or by stromal cells, its production being 
stimulated by interactions between epithelial cancer cells [96]. Overexpression of HA in 
cancer cells has been found to predict poor survival in colon cancer [97-98], whereas in 
oral squamous cell carcinoma and stage I cutaneous melanoma, a reduction of epithelial 
HA expression correlates with poor survival [99-100]. High levels of stromal HA 
expression correlate with poor survival in ovarian [101], lung [102] and breast cancer 
[103]. High cell-associated HA levels have predicted shorter survival in colon [104] and 
gastric cancers [105]. 
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2.6.3 CD44 
   CD44 is a transmembrane cell surface receptor, which is encoded by a large gene in 
human chromosome11 (11p13). CD44 is composed of 21 exons, 11 of which can be 
variably spliced. CD44 has extracellular, transmembrane and cytoplasmic domains. The 
extracellular domain serves for adhesion to extracellular matrix components, mainly HA 
[106]. The cytoplasmic domain is anchored via ankyrin and ERM (ezrin, radixin and 
moesin) proteins to the actin cytoskeleton and is most important for the functions of 
CD44 in signal transduction and cell migration [107]. Between the transmembrane 
domain and N-terminal globular domain, there is a stalk-like region, which can be 
enlarged by insertion of variably spliced exon products [107]. Alternative splicing gives 
rise to multiple variant isoforms of CD44 (CD44v), which have a longer extracellular 
domain [79]. The most common isoform of CD44 is the standard molecule of CD44 
(CD44s), with a molecular weight of 80-90 kD, which is the shortest of the splice 
variants [108].  
CD44s has been shown to be involved in many biological processes, including cell 
adhesion (aggregation and migration), HA endocytosis, lymphocyte activation, lymph 
node homing, myelopoiesis and lymphopoiesis, angiogenesis and release of cytokines 
[79]. However, the precise functions of variant CD44 are not yet entirely clear [108]. In 
ovarian cancer, it has been reported that CD44 mediates the binding of ovarian cancer 
cells to the peritoneal mesothelium via an interaction of HA in vitro [21-22]. The next 
step in tumor growth, the migration of ovarian cancer cells towards the extracellular 
matrix has been also shown to be regulated by an interaction between CD44 and HA. 
However, as Casey et al reported, this finding could also be cell-line specific [16]. 
Kokenyasi et al have suggested that ovarian cancer cells can use several molecular 
mechanisms to adhere to the complex extracellular matrix of the peritoneum, including 
integrins, CD44 and cell surface lectins. For this reason, they concluded that therapeutic 
efforts to prevent metastatic spread would be successful only if CD44 could interfere 
with multiple adhesion mechanisms [109]. According to in vitro studies, CD44 serves to 
anchor MMP-9 and localizes proteolytically active MMP-9 to the tumor cell surface, 
thus promoting the CD44-mediated invasion [110]. Another in vitro study has shown 
that the tumor cells grown on HA and collagen, and cultured in the presence of a CD44-
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activating antibody, express a greater amount of MMP-9, leading to increased invasion 
and migration of tumor cells [91]. 
In vivo, CD44s and CD44 variant isoforms are expressed in many normal and 
malignant tissues [108][111]. The standard form of CD44 is the major species in 
ovarian cancer, but splice variants are also expressed [79][111-114]. It has been found 
that CD44 expression is highest in borderline tumors, as compared to malignant and 
benign tumors. However, malignant tumors express more CD44 than benign tumors 
[115-117]. 
The results in the literature on the prognostic role of CD44s in ovarian cancer are 
inconsistent. In relatively small patient cohorts (N=31-115), high CD44 expression in 
ovarian carcinoma has been associated with good prognosis [113][117], five studies 
have detected no association at all [111][115][118-120], and two studies suggest poor 
prognosis with high CD44 [114][116] (Table 6). 
 
Table 6. Prognostic studies on CD44s using immunohistochemical methods 
prognosis:   
Author (Ref) year N= antibody 
univariate (UV)/ 
multivariate (MV) 
Cannistra et al [111] 1995 31 Clone 25.32 R&D Systems No significance 
Kayastha et al [114] 
 
1999 
 
56 
 
anti-CD44s monoclonal  
antibody Bender MedSystems 
UV and MV: High CD44s 
associates with poor DFS 
Saegusa et al [119] 
 
 
1999 
 
 
115 
 
 
Anti-h phagoc. glycop-1  
mouse monoclonal antibody 
Dako 
No significance 
 
 
Berner et al [118] 
 
2000 
 
67 
 
Anti-CD44s monoclonal  
antibody Bender MedSystems 
No significance 
 
Ross et al [117] 
 
 
 
2001 
 
 
 
64 
 
 
 
A3D8 mouse monoclonal  
antibody Sigma 
Immunochemicals 
 
UV:Loss of CD44s 
associates with poor 
survival 
MV:no significance 
Schroder et al [120] 
 
1999 
 
50 
 
Anti-CD44s monoclonal  
antibody Bender MedSystems 
No significance 
 
Rodriquez-Rodriques 
 et al [113] 
 
2003 
 
 
142 
 
 
Anti-CD44s, R&D Systems 
 
 
UV:High epithelial and 
stromal CD44s associates 
with better survival 
Zagorianakou et al [115] 2004 83 CD44(DF 1485) Dako No significance 
Cho et al [116] 
 
2006 
 
95 
 
 DF1485, DiNonA 
 
UV and MV: High CD44s 
associates with poor DFS 
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2.6.4 Matrix Metalloproteinases 
    Matrix metalloproteinases (MMPs) are a family of at least 21 human zinc-dependent 
endopeptidases capable of degrading any extracellular matrix protein [17]. Matrix 
metalloproteinases (MMPs) were previously divided into five groups: a) collagenases, 
b) gelatinases, c) stromelysins, d) membrane-type MMPs (MT-MMPs), and e) others 
(MMP-7) [18]. This division was based on their specificity at degrading different ECM 
components. However, as the list of MMP substrates has grown, MMPs are now 
grouped into eight classes according to their structure; five are secreted and three are 
membrane-type MMPs. The secreted MMPs are as follows; minimal domain MMPs, 
simple hemopexin-domain-containing MMPs, gelatin binding MMPs, furin-activated 
secreted MMPs and vitronectin-like insert MMPs. The membrane-type MMPs are 
classified as transmembrane MMPs, GPI-anchored MMPs and type II transmembrane 
MMPs [17]. The general structure of the MMPs is shown in Figure 2. 
 
 
  
 Amino-terminal signal 
                sequence  (ATSS, pre)      Vitronectin-like insert      
 Fi 
 
 
 
 
 
              Propeptide            Catalytic               Hinge    Hemopexin   Transmembrane 
 
 
 
Fig 2 The domain structure of MMPs. ATSS (pre) directs MMPs to the endoplasmic reticulum 
and the N-terminal propetide domain maintains the MMPs in an inactive form. The catalytic 
domain consists of a zinc-binding site (Zn). The hemopexin-like domain which mediates 
interactions with the tissue inhibitors of metalloproteinases (TIMP),  cell-surface molecules and 
proteolytic substrates, is connected to the catalytic domain by a hinge. The transmembrane 
domain exists only in membrane-type MMPs.Fi is insert that resemble collagen-binding type II 
repeats of fibronectin. Fu is a recognition motif for intracellular furin-like serine proteinases, 
which allows intracellular activation of these proteinases.   Modified from Egeblad and co-
workers, and Curran and co-workers[17-18] 
 
Zn 
Fu 
 31 
 
2.6.4.1 Secreted MMPs 
 
   Minimal domain MMPs, MMP-7 (matrilysin; PUMP1, matrin) and MMP-26 
(matrilysin-2, endometase), contain only those domains absolutely essential for 
secretion and activity (i.e. pre, pro, and catalytic domains) (Fig 2A)[17]. MMP-7 has 
been found to cleave many ECM components (fibronectin, gelatins, collagen type IV) 
and proMMPs (i.e. gelatinase A and B), as well as a miscellaneous group of other 
proteins (i.e. casein, insulin, TNF-alpha precursor) [121-122]. MMP-7 is also able to 
activate pro-forms of MMP-2 and –9 [122-123]. The substrates of MMP-26 are laminin, 
fibronectin, denatured collagen and collagen IV and V [124]. 
 
  Amino-terminal signal 
                sequence  (ATSS, pre)       
  
   
 
 
 
 
 
               Propeptide            Catalytic              
 
Fig 2A The domain structure of minimal-domain MMPs. Modified from Egeblad and co-
workers, and Curran and co-workers [17-18]. 
   
   The simple hemopexin-domain-containing human MMPs include MMP-1 
(collagenase-1), MMP-3 (stromelysins-1), MMP-8 (collagenase-2), MMP-10 
(stromelysin-2), MMP-12 (metalloelastase), MMP-13 (collagenase-3), MMP-18 
(collagenase-4), MMP-19 (RASI-1), MMP-20 (enamelysin), and MMP-27  [17]. These 
MMPs contain ATSS, propeptide, catalytic, hinge and hemopexin-like domains (Fig 
2B) [17] and they are capable of degrading many proteoglycans, laminin, gelatins, 
collagens I, II, III, IV, V, VII, IX and X, fibronectin, entactin, versican, tenascin, 
osteonectin, hyaluronidase-treated versican, aggrecan and amelogenin [125-126]. These 
MMPs can be involved an activation cascades; MMP-1 and MMP-13 activate MMP-2, 
futher more MMP-3 and MMP-10 have been shown to activate MMP-1,-7,-8,-9 and –13 
[126].  
 
Zn 
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                     Amino-terminal signal 
                                           sequence  (ATSS, pre)       
  
 
 
 
 
 
                  Propeptide            Catalytic             Hinge           Hemopexin       
 
Fig 2B The domain structure of simple hemopexin-domain-containing MMPs. Modified from 
Egeblad and co-workers, and Curran and co-workers [17-18]. 
 
   MMP-2 (gelatinase A; 72-kD type IV collagenase) and -9 (gelatinase B; 92-kD type 
IV collagenase) belong to gelatin-binding MMPs, previously called the gelatinase 
subgroup. MMP-2 and MMP-9 consist of amino-terminal signal sequences, propetide, 
catalytic, hinge, hemopexin domains and also (Fi) inserts that resemble collagen-
binding type II repeats of fibronectin (Fig 2C) [17]. These MMPs are able to cleave type 
IV collagen, the major structural components of basement membranes (BMs) and 
denatured interstitial collagen (gelatin) [18-19]. In addition, these MMPs can degrade 
elastin, fibronectin, laminin-1 and –5, aggrecan, decorin, hyaluronidase-treated versican, 
and osteonectin [126]. MMP-2 can activate also MMP-9 and -13 enzymes [126]. 
 
                    Amino-terminal signal 
                                  sequence (ATSS, pre)        
 Fi 
 
 
 
 
 
        Propeptide              Catalytic              Hinge         Hemopexin 
 
Fig 2C The domain structure of gelatin-binding MMPs. Modified from Egeblad and co-
workers, and Curran and co-workers [17-18]. 
 
   The furin-activated secreted MMPs include MMP-11 (stromelysin-3) and MMP-28 
(epilysin). These MMPs contain the same parts as the simple hemopexin-domain 
Zn 
Zn 
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containing MMPs, and additionally a recognition motif for intracellular furin-like serine 
proteinases, located between the propeptide and catalytic domains (Fig 2D) [17]. The 
substrates of MMP-11 are reportedly casein, lamin, fibronectin, gelatin and collagen IV, 
whereas substrates of MMP-28 are still unknown [126]. 
 
Amino-terminal signal 
              sequence (ATSS, pre)        
  
 
 
 
 
 
              Propeptide                        Catalytic            Hinge       Hemopexin       
 
Fig 2D The domain structure of furin-activated secreted MMPs. Modified from Egeblad and co-
workers, and Curran and co-workers [17-18]. 
 
   MMP-21 (Homologue of Xenopus XMMP) is classified as a vitronectin-like insert 
MMP. This MMP contains the same parts as the furin-activated MMPs, plus the 
vitronectin-like insert (Fig 2E) [17]. Substrates of this MMP are still unknown [124]. 
 
  Amino-terminal signal 
                sequence (ATSS, pre)     Vitronectin-like insert      
  
 
 
 
 
 
             Propeptide                        Catalytic            Hinge      Hemopexin 
 
Fig 2E The domain structure of vitronectin-like insert MMPs. Modified from Egeblad and co-
workers, and Curran and co-workers [17-18]. 
 
 
Zn 
Fu 
Zn 
Fu 
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2.6.4.2 Regulation of expression and activity of secreted MMPs 
 
   Many physiological regulators of MMP transcription have been characterized, and 
these include cytokines, growth factors, chemokines, bacterial endotoxin, phorbol 
esters, hormonal stress and oncogenic transformation [127-128]. In addition, cell-matrix 
and cell-cell interactions can regulate MMP gene expression [128]. Extracellular matrix 
metalloproteinase inducer (EMMPRIN) has been proposed to induce the synthesis of 
several MMPs, particularly MMP-1, -2 and -3 [127]. Beta–catenin combination with the 
DNA binding protein TCF can transcriptionally regulate MMP-7 expression [129-130]. 
It has also been shown that the presence of HA can influence the expression of MMP-2 
and -9 [91][93-94]. Stimulation of CD44 by HA has been shown to increase the 
secretion of MMP-2 and –9 in vitro [91-92][94] and in vitro studies have also shown 
that activation of MMP-2 and –9 secretion and the elevated invasiveness induced by HA 
can be blocked by the expression of antisense CD44s [91][94].  
Most of the MMPs are secreted as inactive zymogens in a soluble form, requiring 
activation. This activation occurs in the extracellular milieu either by a plasminogen 
activator-plasminogen cascade system, or by another member of the MMP family 
[123][126]. Activation of pro-MMP-2 is a multistep process which takes place on the 
cell surface, starting with formation of MT1-MMP/TIMP-2 complex, proceeding on by 
binding of pro-MMP-2 and its activation by an adjacent TIMP-free active MT1-MMP 
molecule [131-132]. It has also been shown that the presence of HA can influence the 
conversion of the inactive pro-forms of MMP-2 and -9 to their active state [91][93-94]. 
The prodomain of MMPs must be removed to free the active site so it can perform 
catalysis [133].  
   In the tissues, MMP activity is regulated by a group of endogenous proteins, the tissue 
inhibitors of metalloproteinases (TIMPs). Four TIMPs (TIMPs-1 to 4) have been 
identified to date [128]. TIMP-1 and TIMP-2 inhibit the activity of most MMPs , except 
MT1-MMP. TIMP-3 inhibits the activity of MMP-1, -2, -3, -9 and –13 and TIMP-4 
modulates the activity of MMP-2, -7 and reduces the activity of MMP-1, -3 and –9 
[134]. By inhibiting MMP activity, the TIMPs can decrease tumor growth and 
metastasis. Apart from inhibition of MMPs, the TIMPs have a more complex role in 
cancer, as they also favor tumor growth by inhibiting apoptosis, stimulating 
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angiogenesis and activating pro-MMP-2. These functions can be either MMP dependent 
or independent [135]. Overexpression of TIMP-2 and down-regulation of TIMP-1 have 
been suggested to contribute to ovarian tumorigenesis [136-137] and  the extent of 
TIMP-2 expression has been correlated with poor survival of the patients [138-139]. 
However, TIMP-1 concentrations are higher in carcinoma/borderline cyst fluids than in 
adenoma cyst fluids [140].  
 
2.6.4.3. Secreted MMPs in cancer progression 
    MMPs have a critical role in the regulation of tumor progression. Cell adhesion is a 
physiological restrictor of cell divisions, mediated through different adhesion 
molecules, for example cadherins, catenins and integrins. MMPs can influence cell 
adhesion by processing different adhesion molecules [15]. A key differentiation event 
during cancer progression is the epithelial-to mesenchymal transition (EMT), during 
which epithelial cells are transformed into mesenchymal or fibroblast-like cells, which 
can facilitate their migration. MMP-7 and MMP-3 can trigger EMT by cleavage of E-
Cadherin [15]. MMPs are classically also involved in the next step in cancer 
progression, invasion and metastasis [15]. MMP-2 and –9 are the most important MMPs 
that facilitate migration of tumors cells by degrading the basement membrane [141]. 
During migration, cancer cells have to detach both from neighboring cells and the 
surrounding matrix. CD44 can also bind to MMP-9, and localize it on the cell surface, 
to promote tumor invasion and angiogenesis.  
Apoptosis has an important role during tumor progression, and MMP-7 has been 
shown to trigger apoptosis upon binding with the Fas receptor, but it has been also 
shown to inhibit apoptosis by stimulating the ErbB4 tyrosine kinase receptor [15][17]. 
MMP-2, -3, -7, -9 and –12 limit angiogenesis and cancer progression by generating 
angiostatin from plasminogen [17][142-143]. However, MMPs also promote 
angiogenesis by degrading barriers and by liberating factors that promote or maintain 
the angiogenic phenotype [144]. Stromal MMP-9 expression has been shown to 
enhance angiogenesis, growth and the formation of ascites in human ovarian cancer in 
nude mice [85]. 
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2.6.4.4. Expression and prognostic significance of MMP-2, -7 and –9 in different tumors 
   Overexpression of MMP-2, -7 and -9 has been found in numerous tumors, including 
ovarian epithelial cancer [123][145-153]. In samples obtained from normal ovary and 
benign lesions, MMP-2 and -9 are expressed in epithelial cells, but also in the stromal 
area [148-151][154-156]. Previous studies within malignant ovarian tumors have shown 
that both stromal and epithelial cells express MMP-2 and -9 [138][152][155-160]. 
MMP-7 is mainly expressed in tumor cells, unlike other MMPs which are found both in 
tumors cells and in tumor stroma, a finding also present in epithelial ovarian cancer 
[123][145-147][161-163].(Table 7.) 
In many malignant tumors, increased expression of MMPs associates with a poor 
outcome of the disease [164], but opposite findings have also been reported [154][165-
168]. However, only a few immunohistochemical studies with relatively small patient 
cohorts have investigated the prognostic significance of MMP-2 and -9 in epithelial 
ovarian cancer, and the results of these studies are controversial [148-149][152][154-
155][160][169](Table 8.)  
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Table 8. Immunohistochemical studies on the association of MMP-2 and –9 
expressions and prognosis in ovarian cancer 
prognosis:   
Author (Ref) year N= antibody univariate (UV)/multivariate (MV) 
De Nictolis et 
al [148] 1996 18 
Prepared themselves, 
affinity-purified 
MV: no significance 
 
Garzetti et al 
[149] 1995 21 
Prepared themselves, 
affinity-purified 
UV and MV:MMP-2 positivity in cancer cells 
associates with short DFS 
Westerlund et 
al [155] 1999 33 
Diabor Ltd 
 
UV: MMP-2 negative stroma and positive cancer 
cells associate with short DRS 
Torgn et al 
[160] 2004 84 
Oncogene Research 
 
UV:stromal  MMP-2 positivity associates with 
poor DFS and RFS 
Kamat et al 
[169] 
 
 
2006 
 
 
 
90 
 
 
 
Labvision Neomarkers 
(MMP-2) 
Oncogene Research 
Products (MMP-9) 
UV:High epithelial and stromal expression of 
MMP-2 and -9 associates with short DSS 
MV:High stromal MMP-9 indicates poor DSS 
 
Lengyel et al 
[152] 
2001 
 
84 
 
Triple points 
 
UV: High pro-MMP-9 associates with short OS 
MV: Pro-MMP-9 indicates short OS 
Ozalp et al 
[154] 
2003 
 
30 
 
Neomarkers 
 
UV: High MMP-9 in epithelium, tendency to long 
OS, Stromal MMP-9 associates with short OS 
2.6.5 EMMPRIN 
   Extracellular matrix metalloproteinase inducer (EMMPRIN, also called Basigin and 
CD147) is a plasma membrane-bound glycoprotein. Purified EMMPRIN, derived from 
human tumor cell membrane, has been suggested to induce the synthesis of various 
MMPs [127]. EMMPRIN was found during a search for factors inducing MMPs [173]. 
The protein portion of EMMPRIN is 34kDa, while its glycosylated form has a 
molecular weight of 62-90kDa [174].  
EMMPRIN has been shown to stimulate the production of interstitial collagenase 
(MMP-1), gelatinase A (MMP-2), and stromelysin-1 (MMP-3) in human fibroblasts in 
vitro [175]. EMMPRIN stimulates the production of MMPs in fibroblasts and 
endothelial cells [175-178]. It has also been reported that overexpression of EMMPRIN 
in fibroblasts [179] and tumor cells [178][180] leads to increased MMP production 
within the same population of cells. A correlation between EMMPRIN and MMP-9 has 
been noted, but no clear evidence has been reported on weather EMMPRIN can 
stimulate the rate of MMP-9 synthesis [173]. In addition to stimulating various MMPs 
in cancer tissues, EMMPRIN is involved in normal development and non-tumoral tissue 
remodelling [173]. These include activation and development of T cells, functioning as 
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a receptor for cyclophilin A, and upregulating of the expression of VEGF (vascular 
endothelial growth factor) and HA [181].  Recently, cancer cell-associated EMMPRIN 
has been shown to stimulate the production of HA, probably due to elevated expression 
of HA synthases [182].  
EMMPRIN is expressed both in normal and different tumor tissues [183-185]. 
EMMPRIN mRNA and protein are localized in cancer cells as well as in peritumoral 
stromal cells, also in serous ovarian carcinoma [183][186]. In addition, EMMPRIN 
mRNA and protein levels are elevated in many carcinomas compared to benign and 
normal tissues [183][187-189]. In human breast, laryngeal and renal cancers, positive or 
high staining for EMMPRIN in cancer cells has associated with poor survival of the 
patients [187][190-191], whereas in hepatocellular carcinoma no significant association 
has been detected between survival and EMMPRIN expression in cancer cells [192]. 
Previously, only one study has investigated the prognostic value of EMMPRIN in 
ovarian cancer and that study included only serous tumors [186]. Davidson and co-
workers concluded that, EMMPRIN protein expression in stromal cells correlates with 
poor survival [186].  
2.6.6 Cadherin-catenin complex 
   Epithelial (E-) cadherin is a transmembrane glycoprotein which mediates cell-cell 
adhesion in a calcium-dependent manner [75][193]. E-cadherin is bound to the 
cytoskeleton via a family of proteins called catenins, which lie under the plasma 
membrane [75]. The E-cadherin –catenin complex regulates the functional integrity of 
epithelial cells.  In the normal situation, the function of E-cadherin is dependent on its 
linkage to catenins (α-, β-, γ- catenin). E-cadherin is known to bind γ- and β-catenins, 
which link E-cadherin to α -catenin and the actin cytoskeleton [193]. Loss of E-
cadherin allows malignant cells to disaggregate from each other, after which these cells 
can easily invade adjacent areas, and also metastasize [75]. Alterations in any 
component of the cadherin-catenin complex may cause disruption in function [194].  
In different human cancers, including epithelial ovarian cancer, expression of E-
cadherin is reduced compared to the corresponding normal tissue and benign lesions 
[194-195]. E-cadherin expression has an invasion-suppressor function [194][196]. 
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Wijnhoven et al concluded that E-cadherin and catenins are more strongly expressed in 
well-differentiated and less invasive tumors compared to poorly differentiated and 
invasive tumors [194]. Therefore, it seems that changes in E-cadherin/catenin 
expression may influence cancer development and progression. Recent reviews have 
agreed that there is a strong positive correlation between disturbances in the E-
cadherin/catenins, and a poor prognosis in many tumors, including ovarian cancer [194-
198]. However, the prognostic significance E-cadherin/catenin complex has not been as 
strong as the traditional clinicopathological factors [194].  
β-catenin is mainly located on the cell membrane, where it mediates cell adhesion. 
Loss of β-catenin expression on the cell membrane correlates with poor prognosis in 
ovarian cancer [197](Table 9). In addition to its location on the cell membrane, β-
catenin can be found in smaller quantities in the cytoplasm and nucleus. The nuclear β-
catenin is involved in the Wnt signaling pathway [193](Table 9), which plays a key role 
in cell proliferation and differentiation and involves proteins that directly participate in 
both gene transcription and cell adhesion [130][199]. Free β-catenin is usually degraded 
by the proteasomes, however, mutated β-catenin can avoid degradation, which results in 
its cellular accumulation. After translocation to the nucleus, β-catenin binds and 
activates the transcription factor TCF, which increases the transcription of a large set of 
genes, such as E-cadherin, c-myc, cyclin D1, MMP-7 and CD44 [129-130][200]. The 
adenomatous polyposis coli (APC) tumor suppressor gene product and E-cadherin act as 
downregulators of this beta-catenin/TCF dependent transcription [199]. Oncogenic β-
catenin mutation is typically found in the endometrioid type of ovarian carcinomas, 
characterized by nuclear accumulation of β-catenin [201-203]. Catasus et al showed that 
7/11 ovarian tumors, which showed nuclear β-catenin positivity exhibited oncogenic 
mutations [204]. The mutation increases the expression of MMP-7 in these tumors 
[172]. Nuclear β-catenin has also been noted in colorectal and esophageal cancers [205-
206]. Nuclear β-catenin expression is an indicator of favorable outcome in epithelial 
ovarian cancer [201]. 
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Table 9. Recent publications concerning the expression of β-catenin in epithelial 
ovarian cancer using immunohistochemistry 
Author (Ref) Year N 
expression  
m /c / n 
        
clinicopathological  
        correlations 
     Prognostic 
     significance 
Cho [116] 
 
2006 
 
95 
 
m 74.7% 
n 1.1% 
(n and m) NS 
 
(n and m) NS 
 
Davidson [207] 2000 97 m 100% ND ND 
Fujioka [208] 
 
2001 
 
49 
 
m 92% 
n 5% 
(n) NS 
 
(m) NS 
 
Davidson [198] 
 
 
2000 
 
 
75 
 
 
m 91% 
n 0% 
 
membranous positivity  
associates with low 
grade tumors 
ND 
 
 
Lee [209] 
 
 
 
2003 
 
 
 
95 
 
 
 
low grade tumors: 
m 94%/c 34%/n 2.1% 
high grade tumors: 
m 92%/c 39%/n 23% 
nucler positivity 
associates  
with high grade tumors 
 
(n) NS 
 
 
 
Gamallo [201] 
 
 
 
1999 
 
 
 
69 
 
 
 
m 100% 
n 16% 
 
 
 nuclear positivity 
associates 
with endometrioid type 
of tumors 
UV/MV: nuclear 
positivity  
associates good 
RFS/OS(m) NS 
Faleiro-Rodrigues 
 [210] 
 
 
 
2004 
 
 
 
 
104 
 
 
 
 
m 86% 
 
 
 
 
low membranous 
positivity associates 
with clear cell histology 
and high grade of the 
tumor 
ND 
 
 
 
 
Faleiro-Rodrigues 
 [197] 
 
 
 
2004 
 
 
 
 
104 
 
 
 
 
m 86% 
 
 
 
 
membranous positivity  
associates with 
mucinous histology 
 
 
UV/MV:negativity 
of membranous  
expression 
associates with 
poor survival 
Imai [211] 
 
 
2004 
 
 
77 
 
 
m 92% 
n 2% 
 
membranous positivity  
associates low stage of 
the tumors 
ND 
 
 
Marques [212] 2004 47 m+c 65%, n 17% ( m+c) NS ND 
Davies [213] 1998 34 m 79% ND ND 
Wright [214] 1999 149 n 12% ND ND 
Wu [202] 
 
 
2001 
 
 
45 
 
 
all endometrioid 
tumors of ovary 
n 31% 
ND 
 
 
ND 
 
 
Sagae [215] 
 
1999 
 
27 
 
m 85% 
n 14.8% 
ND 
 
ND 
 
NS=non significant, ND= not determined m=membranous, c=cytoplasmic, n=nuclear 
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3. AIMS OF THE STUDY 
   The aim of the present study was to evaluate possible new prognostic factors in 
epithelial ovarian cancer. These factors were investigated in association with the 
conventional clinicopathological factors and hyaluronan. The general aim of the study 
was to increase current knowledge on the biology of epithelial ovarian cancer. The 
specific aims of the study were: 
 
1. To study the expression of CD44 and its association with HA, clinicopathological 
factors and prognosis in epithelial ovarian cancer (I). 
 
2. To evaluate the expression and prognostic value of MMP-7 in epithelial ovarian 
tumors, as well as its association with clinicopathological factors and nuclear β-catenin 
expression (II). 
 
3. To investigate the expression and prognostic significance of MMP-9 in epithelial 
ovarian cancer and to study its relation to CD44 and HA expressions, and 
clinicopathological factors (III). 
 
4. To analyze the expression and prognostic value of EMMPRIN and MMP-2 in 
normal, benign and malignant epithelial ovarian tissue, as well as to study their relation 
to each other, HA expression as well as with clinicopathological factors (IV). 
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4. MATERIAL AND METHODS 
4.1 Patients 
   Epithelial ovarian cancer patients of the present retrospective study were originally 
selected from a consecutive series of 445 women diagnosed and treated for ovarian 
malignancy in Kuopio University Hospital and Jyväskylä Central Hospital, Finland, 
between 1976 and 1992 and subsequently followed-up until January 2004 [101]. 
Borderline tumors were excluded from the study. On the basis of the availability of 
representative tumor material, tumors from 307 patients were finally selected for this 
study. Patients treated before surgery or patients who were not operated on, were not 
included. Patients who died because of any post-operative complications (deaths during 
one month after operation) were not included into the survival analyses. According to 
the above criteria, altogether 284-307 patients were finally included in these analyses 
(Table 10). 
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Table 10. Clinicopathological data of the patients in each publication (I-IV) 
Characteristic 
CD44 
 
I   
MMP-7  
 
II   
MMP-9  
 
III   
EMMPRIN 
and MMP-2 
 IV   
  n % n % n % n % 
Number of patients 307  284  292  295 
 
Age,years         
  Median 62  62  62  61  
  Range 18-85  18-85  21-85  18-85  
Histological grade         
1 43 (14) 40 (14) 42 (14) 40 (14) 
2 104 (34) 97 (34) 99 (34) 100 (34) 
3 160 (52) 147 (52) 151 (52) 155 (52) 
Histological subtype         
   Serous 109 (36) 102 (36) 105 (36) 104 (35) 
   Mucinous 31 (10) 28 (10) 29 (10) 27 (9) 
   Endometrioid 82 (27) 76 (27) 80 (27) 81 (28) 
   Clear cell 32 (10) 28 (10) 29 (10) 31 (10) 
   Miscellaneous* 53 (17) 50 (17) 49 (17) 52 (18) 
FIGO stage         
I 84 (27) 77 (27) 79 (27) 80 (27) 
II 47 (15) 44 (15) 42 (14) 47 (16) 
III 144 (47) 132 (47) 140 (48) 137 (46) 
IV 32 (10) 31 (11) 31 (11) 31 (11) 
Primary residual tumor         
   No data 26 (8) 24 (8) 26 (9) 26 (9) 
   None 122 (40) 113 (40) 114 (39) 117 (40) 
   <2 cm 51 (17) 48 (17) 49 (17) 50 (17) 
   >2 cm 108 (35) 99 (35) 103 (35) 102 (34) 
First line chemotherapy         
   platinum based 164 (53) 151 (53) 155 (53) 154 (52) 
   non-platinum based 97 (32) 90 (32) 93 (32) 94 (32) 
   none 44 (14) 40 (14) 41 (14) 44 (15) 
   no data 2 (1) 3 (1) 3 (1) 3 (1) 
Chemotherapy response  
   No data 6 (2) 6 (2) 7 (2) 6 (2) 
   PR  39 (13) 38 (13) 38 (13) 38 (13) 
   CR 140 (47) 131 (46) 133 (46) 134 (45) 
   SD 22 (7) 19 (7) 22 (7) 21 (7) 
   PD 56 (19) 50 (18) 51 (18) 52 (18) 
   No chemotherapy 44 (11) 40 (14) 41 (14) 44 (15) 
Status at the end of 
follow-up   
    
  
   Dead 198 (66) 210 (74) 219 (75) 222 (75) 
   Alive 100 (34) 74 (26) 73 (25) 73 (25) 
* includes mixed epithelial, unclassified epithelial and malignant Brenner tumors  
PR, partial response; CR, complete response; SD, stable disease; PD, progressing disease 
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4.2 Histology 
   Histological types and grades of the tumors were evaluated according to the WHO 
classification and borderline tumors were excluded from the study [216]. 
4.3 Immunohistochemical analyses 
   The main protocol for immunohistochemical staining was similar in all stainings, and 
was modified depending on the antibody being used (Table 11). The five-µm-thick 
tumor sections were deparaffinized and rehydrated using xylene and graded alcohols. 
To achieve better antigen retrieval, the samples were heated 3x5 min in a microwave 
oven in a citrate or EDTA buffer. Endogenous peroxidase activity was blocked by 5% 
hydrogen peroxide for 5 min, followed by 2×5 min washings with PBS. Non-specific 
binding was blocked with 1.5 % normal horse serum (Vectastain ABC Elite kit, Vector 
Laboratories, Burlingame, CA, USA) in PBS for 45 min at room temperature. The 
slides were incubated overnight at 4°C with the primary antibody in PBS (antibodies 
listed in table 11). The slides were incubated with the biotinylated secondary antibody 
(anti-mouse IgG; ABC Vectastain Elite kit) for 45 min at room temperature and washed 
twice for 5 min in PBS. The sections were then incubated for 50 min in preformed 
avidin-biotinylated peroxidase complex (ABC Vectastain Elite kit, Vector 
Laboratories). The color was developed with diaminobenzidine tetrahydrochloride 
(DAB) (Sigma, St. Louis, MO, USA), and the sections counterstained with Mayer´s 
haematoxylin. After washing, the slides were dehydrated, cleared and mounted with 
DePex (BDH, Poole, UK). In the negative controls, the primary antibody was omitted.  
In CD44 analysis, about 20% of the samples were stained with another CD44 antibody 
(monoclonal mouse anti-human CD44, clone DF 1485; Dako Cytomation, Glostrup, 
Denmark). In MMP-7 analysis, 36 specimens were incubated with mouse monoclonal 
anti-human MMP-7 (clone ID-2, Chemicon International; 1:50 dilution), which reacts 
with the pro- and active forms of human MMP-7. 
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Table 11. Antibodies used in immunohistochemical analyses. 
Marker  
(study number) Antibody 
Dilutio
n Manufacturer 
Antigen 
retrieval recogonizes  
CD44 (I) 
 
clone 2C5 
 
1:1200 
 
R&D Systems 
 
microwave+ 
citrate buffer 
all forms of 
 CD44 
MMP-7 (II) 
 
clone 141-7B2 
 
1:800 
 
Chemicon  
International 
microwave+ 
citrate buffer 
pro-form 
of MMP-7 
MMP-9 (III) 
 
 
clone 56-2A4 
 
 
1:2500 
 
 
Chemicon  
International 
 
microwave+ 
citrate buffer 
 
pro-and 
active forms 
of MMP-9 
MMP-2 (IV) 
 
 
MAB 13431 
 
 
1:100 
 
 
Chemicon  
International 
 
microwave+ 
citrate buffer 
 
pro-and 
active forms 
of MMP-2 
EMMPRIN (IV) 
 
8D6 sc-2174 
6 
1:100 
 
Santa Cruz  
Biotechnology 
microwave+ 
EDTA buffer 
all forms of 
EMMPRIN 
β-catenin (II) 
 
clone 14 
 
1:1000 
 
Transduction 
laboratories 
microwave+ 
citrate buffer 
 
 
4.4 Histochemical analysis of hyaluronan 
   The biotinylated complex of the HA binding region of aggrecan and link protein 
(bHABC) was prepared from bovine articular cartilage and tested for purity. The 
sections were deparaffinized in xylene, rehydrated with graded alcohols, and washed 
with 0.1 M sodium phosphate buffer [PB (pH 7.4)]. Endogenous peroxidase was 
inactivated with 1% hydrogen peroxide for 5 min, and the nonspecific probe binding 
was blocked with 1% BSA in PB. The sections were incubated in bHABC (2.5 µg/ml; 
diluted in 1% BSA) overnight at 4°C. The slides were washed with PB, incubated with 
avidin-biotin-peroxidase (ABC Vectastain Elite kit; Vector Laboratories, Burlingame, 
CA), and washed with PB. The color was developed with 0.05% diaminobenzidine 
tetrahydrochloride (Sigma, St. Louis, MO) and 0.03% hydrogen peroxide in PB. The 
slides were counterstained with Mayer’s hematoxylin for 2 min, washed, dehydrated, 
and mounted in Depex (BDH, Poole, United Kingdom). The specificity of the staining 
was controlled by digesting some of the sections with Streptomyces hyaluronidase in the 
presence of protease inhibitors before the staining or by blocking the bHABC probe by 
preincubation with hyaluronan oligosaccharides [101][217-218]. 
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4.5 Immunoblotting analyses of MMP-7, MMP-9 and EMMPRIN 
   The frozen tissue samples were homogenized, incubated on ice for 30 min, and 
centrifuged at 13,000 rpm for 15 min at 4 °C. After centrifugation, the supernatants 
were stored at –70°C until analysis. The samples were boiled for 5 min with an equal 
amount of SDS sample buffer (0.125 M Tris-Cl, 4% SDS, 20% glycerol, 10% 2-
mercaptoethanol, pH 6.8). Next, the samples were separated on 8% SDS-PAGE and 
transferred onto a nitrocellulose membrane (Hybond ECL, Amersham, Germany) by 
electroblotting. After washing, the membrane was treated with the blocking solution of 
0.1% soy PBS-Tween buffer for 1h and then incubated with the primary antibody for 
1h. The primary antibodies used in immunoblotting are listed in Table 12. The 
horseradish peroxidase-conjugated secondary antibody (1:20000) was applied after 
washing with PBS-Tween buffer and the filter was incubated for 45 min. After 
repeating the washing, the signals were visualized using a substrate kit (Pierce, Super 
Signal West Pico Chemiluminescent Substrate Kit, USA). A set of prestained markers 
and biotinylated low range markers (Bio Rad, CA, USA) were run in parallel with the 
samples. 
Table 12. Antibodies used in the immunoblotting analyses. 
Marker  
(study number) Antibody Dilution Manufacturer 
MMP-7 (II) clone 141-7B2 1:2250 Chemicon International 
MMP-9 (III) clone 56-2A4 1:2250 Chemicon International 
EMMPRIN (IV) 8D6 sc-21746 1:200 Santa Cruz Biotechnology 
 
4.6. Evaluation of the stainings 
   All slides were evaluated with a light microscope and the observers (S.S. and 
K.V./M.A./V.-M.K./K.H.) were unaware of the clinical data of the patients. At least 10 
randomly selected areas were calculated using 400 x magnification. Tissue samples 
consisting of more than 300 tumor cells detected semiquantitatively were included in 
the analyses and slides showing no invasive cancer, were excluded from the analyses. 
The percentage of positive tumor cells of the total tumor cells was analysed by using a 
continuous scale (0-100%). The stromal expression was analysed as a percentage of 
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positive stromal area of total stromal area. Metastases and normal or benign tissues 
were evaluated in the same method as primary tumors. 
4.6.1. Hyaluronan 
   The percentage of the strongest stromal HA intensity of the total peri- and 
intratumoral stromal area was graded into three categories (low, <35%; moderate, 35–
75%; and high, >75%), according to the 33rd and 66th percentiles in a frequency 
distribution. HA-positive tumor cells were categorized in two groups, positive and 
negative [101]. 
4.6.2 CD44 
   The percentage of CD44 expression in tumor cells was categorized into two groups 
based on the median value of 10%; low (<10%) and high (>10%). The intensity of 
CD44 was categorized into three grades: 0, negative; 1, weak to moderate; and 2, strong.  
4.6.3 MMP-2, -7 and -9 
   The percentage of MMP expressions was recorded separately for tumor and stromal 
area, and the percentage of cancer cells with strong staining was analysed 
independently. For statistical analyses, the percentages of MMP stainings were divided 
into two groups using the median value as a cut-off. The categories for MMP-2 in 
cancer cells were low (<30%) and high (>30%) and for strong staining: low (< 10%) 
and high (>10%).  The categories for MMP-9 in cancer cells were: reduced (<90%) and 
high (>90%) and for strong staining; low (< 5%) and high (>5%). The area percentages 
of MMP-7 expression were categorized into two groups according to the median value: 
high (>40%) and low (<40%) and similarly high intense (>5%) and low intense (<5%).  
The stromal expression of MMP was divided into low and high according to the median 
value of positively stained matrix (10% for MMP-2 and 60% for MMP-9). Stromal 
expression of MMP-7 was considered as either negative or positive 
 50 
 
4.6.4. EMMPRIN 
   The percentage areas of membranous and cytoplasmic EMMPRIN staining in the 
tumor cells were categorised into two groups according to the median percentage of the 
expression: high (>10%) and low (<10%) EMMPRIN expression on tumor cell 
membrane, and high (>70%) and low (<70%) EMMPRIN expression on tumor cell 
cytoplasm. In addition, stromal expression of EMMPRIN was analysed and considered 
as either negative or positive. 
4.6.5. β-catenin 
    From the total tumor area, the percentage area of tumor cells showing strong 
continuous staining was analyzed and  then categorized into 2 groups according to the 
median percentage of the expression (5%): reduced expression, <5% of the tumor cells 
expressed strong continuous membranous staining; and preserved expression, >5% of 
the tumor cells expressed strong continuous membranous staining. The presence of 
nuclear staining was directly graded into 2 categories: positive or negative. Strong 
cytoplasmic expression of β-catenin was also analyzed and graded as either being 
present or absent [219]. 
4.7 Statistical analyses 
   The statistical analyses were performed using the SPSS computer program package. 
Spearman correlation coefficients and Wilcoxon tests were used to examine the 
relationships between continuous variables. A chi-square test was used in analyzing 
frequency tables. Univariate survival analyses were estimated using the Kaplan-Meier 
method. Multivariate survival analyses were calculated by means of Cox´s proportional 
hazards model in a forward stepwise manner with the log-likelihood ratio significance 
test. Disease related survival (DRS) was defined as the time between the date of surgery 
and the date of death due to ovarian cancer. Recurrence free survival (RFS) was defined 
by the time interval between the date of surgery and the date of recurrence. Probability 
values less than 0.05 were regarded as significant. 
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4.8 Ethical aspect 
   This study plan was approved by the National Authority for Medicolegal Affairs (N:o 
2953/32/300/03) and by the research ethical committee of the Kuopio University and 
Kuopio University Hospital (N:o 4/2003). 
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5. RESULTS 
5.1 Patient Characteristics 
   The clinicopathological data of the patients in each publication (I-IV) are summarized 
in Table 10. The median age of the patients in these studies was 63 years (range 18 to 
85 years). In this study material, eight patients received postoperative radiotherapy, and 
38 of the patients received both radiotherapy and chemotherapy subsequent to operative 
therapy. The last patient to receive only radiation as an adjuvant therapy was treated in 
1985. From those patients who received only adjuvant chemotherapy in addition to 
operative therapy, 53% received platinum-based chemotherapy. In the present material, 
the patients with stage III-IV disease and those with a primary residual tumor, received 
significantly more often platinum-based treatment than non-platinum based adjuvant 
chemotherapy ( p<0.0005 and p<0.0005, respectively). Platinum-based chemotherapy 
was also more frequently used in the patients diagnosed within the last 10 years of the 
study as compared to non-platinum treatments (χ2=72.5 and p<0.0005). Other 
clinicopathological variables did not differ between these two patient groups.   
5.2 Expression of biological factors 
5.2.1 Expression of CD44  
   Only a few epithelial cells within the normal ovary expressed CD44, in contrast to the 
tumor samples where there was frequent cell surface staining for CD44. The mean 
percentage of CD44-positive cells was 20% in the primary tumors (n = 307)(Fig 3A.) 
and 14% in the metastatic lesions (n = 44). In the stromal areas, lymphocytes were 
always CD44 positive. The level of CD44 expression in the primary tumors correlated 
with that of the metastatic lesions (r = 0.61, p<0.0005, Spearman). No statistically 
significant difference (r=0.881, p<0.0005,Spearman and z=-1.88, p=0.06, Wilcoxon 
test) was noted between the two different monoclonal antibodies used (clone 2C5, R&D 
Systems, Abington, UK and clone DF 1485, Dako Cytomation, Glostrup, Denmark), 
which both recognize all forms of CD44. 
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5.2.2 Expression of MMP-2 and –9 
   Normal (n=7) and benign ovarian samples (n=7) showed positive MMP-2 and –9 
expressions in epithelial cells as well as in the stromal area. In malignant tumors, both 
MMP-2 and -9 were expressed in the cytoplasm of the cancer cells as well as in the 
stromal area (Fig 3B and 3C). In primary tumors, the mean percentage of cancer cells 
positive for cytoplasmic MMP-2 staining was 38% and compared to 16% of cells 
expressing strong staining. The mean percentage of MMP-9 expression in cancer cells 
in primary tumors was 87%, with 15% revealing strong staining. MMP-9 expression 
was significantly higher in tumor cells compared to MMP-2 expression (z=-10.33, 
p<0.0005, Wilcoxon test). Stromal staining was detected in 81% of the samples in 
MMP-2 analysis and in 93% of the samples in MMP-9 analysis. In metastases, the 
cytoplasmic expression patterns of MMP-2 and MMP-9 did not differ from those of the 
primary tumor. The stromal MMP-9 expression was significantly increased in 
metastatic lesions as compared to that of the primary tumor (p= 0.014), while stromal 
expression of MMP-2 did not differ from that of the primary tumor. 
5.2.3 Expression of MMP-7 
   The normal ovarian samples (n=8) showed a weak MMP-7 staining in the cytoplasm 
of the epithelial cells and also in the stromal area. In malignant tumors, the mean 
percentage of MMP-7 expression in cancer cells was 46%, with 10% displaying intense 
staining (Fig 3D). The intensity of cancer cell staining was mainly weak in 82% of the 
samples, with intense staining being observed in only 18% of the cases. In stromal cells, 
MMP-7 positivity was found in 54% of the cases. In metastases, the expression patterns 
of cytoplasmic and stromal MMP-7 did not differ from those of the primary tumor (z = -
0.747, p = 0.455 and z = -0.029, p = 0.977, respectively, Wilcoxon test). A good 
correlation between the staining results was observed between the two different 
antibodies used, (clone 141-7B2 and clone ID-2 the former binding to the pro-form of 
human MMP-7 and the latter reacting with pro- and active forms of human MMP-7) (r 
= 0.746, p < 0.0005 for total expression and r = 0.922, p < 0.0005 for intense 
expression). 
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5.2.4 Expression of EMMPRIN 
   EMMPRIN was expressed in the epithelial and stromal areas in normal (n=7) and 
benign ovarian samples (n=7). Immunostaining of EMMPRIN was localised on the 
tumor cell membrane (Fig 3E) and in the cytoplasm, with mean percentages of 20% and 
60%, respectively, in primary tumors. Membranous EMMPRIN staining was strong in 
68% and cytoplasmic staining was weak in 80% of the primary tumors.  A positive 
stromal staining was seen in 80% of the primary tumors and also in 63% of the 
metastases. In the metastases, the expression patterns of membranous and cytoplasmic 
EMMPRIN did not differ from those of the primary tumor (z=-0.20, p=0.84 and z=-
0.91, p=0.36, respectively, Wilcoxon test). 
5.2.5 Expression of β-catenin 
   Two hundred seventy five samples were analyzed both for MMP-7 and β-catenin and 
twenty (7%) of these exhibited nuclear β-catenin positivity (Fig 3F). Fifteen (75%) of 
the samples with nuclear β-catenin positivity were of the endometrioid subtype. Strong 
cytoplasmic staining of β-catenin was observed in 53 (19%) primary tumors of which 
22 were of endometrioid and 4 of clear-cell histology [219].  
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Figure 3. 
A) An endometrioid ovarian carcinoma exhibiting CD44 expression in the cancer cell 
membrane. Scale bar=30µm. B)  Strong MMP-2 expression in epithelial cell and stromal area in 
a clear cell ovarian carcinoma. Scale bar=100µm. C) A serous cancer with strong MMP-9 
positivity in the cytoplasm of the cancer and stromal cells; Bar=100µm. D) Intense MMP-7 
expression in cancer cells in an endometrioid tumor of the ovary (asterisk). Scale bar=30µm. E) 
Membranous EMMPRIN expression in a clear cell type of ovarian tumor. Scale bar=100µm. F) 
Nuclear β-catenin expression in an endometrioid tumor of the ovary (asterisk) (same tumor 
sample as in fig 3 D). Scale bar=30µm. 
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5.3 Interrelationships between biological factors 
5.3.1 Relation of CD44 and HA expression to the staining data of the 
other markers studied 
Table 13.  Interrelationships between CD44 and HA with the MMP-, EMMPRIN and 
β-catenin markers 
Variable  
CD44 
 
cancer cell HA 
 
stromal  
HA 
CD44 cancer cell   p<0.0003, r=0.20 ns 
MMP-7 cancer cell p=0.001, r=0.15 ns ns 
  
strong cancer cell p=0.002, r=0.18 ns ns 
  
stromal  ns ns ns 
MMP-9 cancer cell ns p=0.04, r=-0.10 ns 
  
strong  cancer cell ns ns ns 
  
stromal ns ns p<0.0005, r=0.30 
MMP-2 cancer cell ns p<0.0005, r=-2.49 ns 
  
strong  cancer cell p=0.048, r=0.12 p=0.014, r=-0.15 ns 
  
stromal  ns ns p=0.002, r=0.19 
EMMPRIN membranous ns ns ns 
  
cytoplasmic  ns ns ns 
  
stromal  ns ns ns 
β-catenin membranous  ns ns p=0.036, r=-0.12 
  strong cytoplasmic  ns ns ns 
  nuclear  χ2=8.0; p=0.004 ns ns 
ns= statistically non-significant  
5.3.2 Relation of β-catenin expression to that of MMP-7 
   A high percentage of MMP-7 expression and intense MMP-7 in cancer cells were 
significantly associated with nuclear positivity of beta-catenin (p=0.003, χ2=8.853 and 
p=0.030, χ2=4.713, respectively) in endometrioid cancers. A similar association was 
found also between a high percentage of MMP-7 and intense MMP-7 in cancer cells 
and with strong cytoplasmic positivity of beta-catenin (p<0.0005, χ2=15.714 and 
p=0.027, χ2=4.920, respectively), especially in endometrioid and clear cell subtypes 
(p=0.025, χ2=5.908 and p=0.025, χ2=5.057, respectively). 
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5.3.3 Relation of MMP-7, -2 and -9 expressions to each other and to 
EMMPRIN expression 
   Cancer cell-associated MMP-7 expression correlated weakly with expressions of 
cancer cell-associated MMP-2 and –9 (p=0.022, r=0.140 and p=0.005, r=0.171, 
respectively). Strong MMP-9 expressions in cancer cells correlated significantly with 
that of MMP-2 and strong MMP-2 expressions in cancer cells (p=0.028, r=0.134 and 
p=0.007, r=0.163, respectively). Stromal MMP-7 expression correlated with stromal 
MMP-2 and –9 expressions (p=0.013, χ2=6.1 and p<0.0005, χ2=16.7, respectively), 
and stromal MMP-9 expression correlated significantly with stromal MMP-2 expression 
(p<0.0005, r=0.230).  The relationships of MMPs to EMMPRIN are shown in Table 14. 
 
Table 14. Interrelationships between EMMPRIN and MMPs 
Variable 
membranous 
EMMPRIN 
cytoplasmic 
EMMPRIN 
stromal 
EMMPRIN 
MMP-7  cancer cell ns ns ns 
 strong cancer cell ns ns ns 
 stromal ns ns ns 
MMP-9  cancer cell ns ns ns 
 strong cancer cell ns p=0.024, r=-0.14 ns 
 stromal  ns ns p=0.010, r=-0.15 
MMP-2  cancer cell ns p=0.021, r=0.14 ns 
 strong cancer cell p=0.015, r=0.15 p=0.033, r=0.13 ns 
 stromal ns ns ns 
ns= statistically non-significant  
5.4 Relation of biological factors to clinicopathological data 
5.4.1 CD44 
   Well-differentiated and mucinous tumors displayed high CD44 expression. The 
tumors with high CD44 expression also responded better to adjuvant chemotherapy. 
Low CD44 expression was significantly associated with advanced-stage tumors and 
those with a large primary residual tumor (>2 cm) (Table 15). 
5.4.2 MMP-7  
   A low percentage area of MMP-7 expression in tumor cells (<40%) was significantly 
correlated with high histological grade of the tumor, advanced stage of the tumor and 
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large primary residual tumor. In addition, a low percentage area (<5%) of intense MMP-
7 expression in tumor cells was significantly correlated with advanced stage of the 
tumor (Table 15). 
5.4.3 MMP-9  
   Reduced (<90%) MMP-9 expression in cancer cells was significantly associated with 
poorly differentiated tumors. A low proportion (<5%) of strong MMP-9 expression in 
tumor cells was significantly associated with a high histologic grade, clear cell type and 
an advanced stage of the tumor and with a large primary residual tumor. High stromal 
(>60%) MMP-9 expression was significantly related to advanced stage of the tumor, but 
not with histological grade (Table 15). 
5.4.4 MMP-2  
   A low (<30%) expression of MMP-2 in cancer cells was significantly associated with 
a high histologic grade (grade 3) and endometrioid type of the tumor. Low (<10%) 
expression of strong cell associated MMP-2 was detected more often in endometrioid 
tumors and with large (>2cm) primary residual tumors. High (>10%) stromal MMP-2 
expression tended to correlate with advanced stage tumors and with large primary 
residual tumors (p=0.086 and p=0.081, respectively) (Table 15). 
5.4.5 EMMPRIN  
   A low (<10%) membranous EMMPRIN expression was detected more often in serous 
type of tumors, tumors with advanced stage and with a large primary residual tumor. 
Strong stromal EMMPRIN staining was statistically significantly associated with 
advanced stage tumors (Table 15). 
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Table 15. Relation of the marker expressions to clinicopathological variables  
Variable 
Histological  
subtype 
Histological  
grade 
FIGO  
stage 
Residual 
tumor 
CD44 cancer cell p< 0.0005 p< 0.0005 p< 0.0005      p<0.005 
MMP-7 cancer cell ns p=0.003 p=0.002 p=0.012 
 intense cancer cell ns ns p=0.029 ns 
 stromal ns ns ns ns 
MMP-9  cancer cell ns p=0.006 ns ns 
 strong cancer cell p<0.0005 p=0.0002 p=0.003 p=0.02 
 stromal ns ns p=0.02 ns 
MMP-2  cancer cell p<0.0005 p=0.005 ns ns 
 strong cancer cell p<0.0005 ns ns p=0.028 
 stromal ns ns ns ns 
EMMPRIN membranous p< 0.0005 ns p=0.012 p=0.011 
 cytoplasmic ns ns ns ns 
 stromal   ns ns p=0.032 ns 
ns= statistically non-significant; as tested by chi-square-test 
5.5 Prognostic factors of the study patients 
5.5.1 Clinicopathological factors 
   In the 10-year univariate DRS analysis, the significant predictors of poor survival 
were advanced (III-IV) FIGO stage, high histological grade (grade 3), age at diagnosis 
(>65 years), primary residual tumor (>2cm) and serous histological subtype. Serous 
histological type, a large primary residual tumor (>2cm) and advanced stage (III-IV) of 
the tumor predicted significantly shorter RFS (Table 16). The results on the patients 
who received platinum-based chemotherapy are shown in Table 17. 
  
Table 16. Traditional clinicopathological factors of 10-year survival in univariate 
analysis 
Variable N DRS N RFS 
FIGO stage 301 p<0.00005 163 p=0.0001 
Histological subtype 301 p=0.0390 163 p=0.0066 
Histological grade 301 p=0.0001 163 ns 
Residual tumor 277 p<0.00005 155 p<0.00005 
Age at diagnosis 301 p=0.0016 163 ns 
Adjuvant chemotherapy 298 ns 162 ns 
Statistical significance was analyzed by Kaplan-Meier method (log rank analysis) 
DRS= disease related survival, RFS= recurrence free survival, ns= non-significant 
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Table 17. Traditional clinicopathological factors of 10-year survival in univariate 
analysis for ovarian cancer patients treated with platinum based chemotherapy 
Variable N DRS N 
                                    
RFS 
FIGO stage 164 p<0.00005 79 p=0.0011 
Histological subtype 164 ns 79 p=0.0360 
Histological grade 164 p=0.0197 79 ns 
Residual tumor 151 p<0.00005 76 p=0.0001 
Age at the diagnosis 164 ns 79 ns 
Statistical significance was analyzed by the Kaplan-Meier method (log rank analysis) 
DRS= disease related survival, RFS= recurrence free survival, ns= non-significant 
 
5.5.2 Relation of CD44 expression to survival 
   Both 5-year and 10-year OS and RFS were better in patients with tumors expressing 
high levels of CD44 (Table 18). Results of univariate analysis of the patients who 
received platinum-based chemotherapy are shown in table 19. 
5.5.3 Relation of MMP-2, -7, -9 and EMMPRIN expressions to survival 
   The 10-year DRS was significantly better when the percentage area of MMP-2, -7, –9 
or membranous EMMPRIN staining in cancer cells was high, MMP-2 predicted also 
better RFS. Similarly, the high percentage area of intense expression of MMP-7 in 
cancer cells predicted favorable DRS and RFS, and strong MMP-2 and -9 expression 
favorable DRS (Table 18).  
A high percentage of stromal MMP-2 tended to predict a short DRS (p=0.0721). 
Positivity of stromal MMP-7 predicted significantly poorer RFS and high stromal 
expression of MMP-9 was a significant prognostic factor for short DRS (Table 18). 
Results of univariate analysis including only patients who received platinum-based 
chemotherapy are shown in Table 19. 
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Table 18. 10-year prognostic significance of the markers in univariate analysis 
Variable     N        DRS     N               RFS 
CD44 cancer cell 297 p<0.00005↑ 161 p=0.0001↑ 
MMP-7 cancer cell 276 p=0.0008↑ 151 ns 
 intense cancer cell 276 p=0.0003↑ 151 p=0.005↑ 
 stromal 276 ns 151 p=0.044↓ 
MMP-9 cancer cell 282 p=0.020↑ 152 ns 
 strong cancer cell 282 p=0.050↑ 152 ns 
 stromal 282 p=0.010↓ 152 ns 
MMP-2  cancer cell 274 p=0.006 ↑ 150 p=0.047↑ 
 strong cancer cell 274 p=0.006↑ 150 ns 
 stromal 269 ns 147 ns 
EMMPRIN membranous 283 p=0.013↑ 155 ns 
 cytoplasmic 283 ns 155 ns 
 stromal 283 ns 155 ns 
Statistical significance was analyzed by Kaplan-Meier method (log rank analysis) 
DRS=disease related survival,RFS=recurrence free survival, ns=non-significant,↓= high 
expression of the studied molecule predicts poor survival, ↑= high expression of the studied 
molecule predicts better survival 
  
 
Table 19. 10-year prognostic significance of the markers in univariate analysis 
including only patients who received platinum based chemotherapy . 
Variable N DRS N RFS 
CD44 cancer cell 163 p=0.001↑ 79 p=0.0005↑ 
MMP-7  cancer cell 151 p=0.008↑ 75 p=0.049↑ 
 intense cancer cell 151 p=0.034↑ 75 ns 
 stromal 151 ns 75 p=0.024↓ 
MMP-9  cancer cell 155 ns 76 ns 
 strong cancer cell 155 ns 76 ns 
 stromal 155 p=0.050↓ 76 ns 
MMP-2  cancer cell 149 ns 75 ns 
 strong cancer cell 149 p=0.020↑ 75 ns 
 stromal 147 ns 73 ns 
EMMPRIN membranous 153 ns 75 p=0.028↑ 
 cytoplasmic 153 ns 75 ns 
 stromal 153 ns 75 ns 
Statistical significance was analyzed by Kaplan-Meier method (log rank analysis) 
DRS=disease related survival, RFS=recurrence free survival, ns=non-significant, ↓= high 
expression of the studied molecule predicts poor survival, ↑= high expression of the studied 
molecule predicts better survival 
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5.5.4 Multivariate survival analyses  
   To evaluate the prognostic significance of factors related to tumor biology, the 
multivariate analysis was run including the clinical and histopathological factors; FIGO 
stage, patient age, size of the residual tumor, histological grade of the tumor, adjuvant 
chemotherapy, and histological subtype. For the biological markers studied, factors 
showing an independent prognostic significance in studies I-IV were included into 
analyses; CD44 in RFS, intense MMP-7 in tumor cells in DRS and RFS, and strong 
MMP-2 in tumor cells in DRS. The independent prognosticators in this multivariate 
analysis are shown in Table 20. The result if only patients who received platinum-based 
chemotherapy were included into analyses is shown in Table 21. The results remained 
the same if stromal HA expression was included into analysis. 
 
Table 20. The independent prognostic factors of 10-year DRS (N=235) and RFS 
(N=140) by Cox multivariate analysis. 
Variable Category RR 95%CI p-value 
DRS         
FIGO stage Stage III-IV vs. I-II 1.88 1.14-3.10 0.014 
Histological grade high vs. low to moderate 1.57 1.11-2.22 0.011 
Residual tumor positive vs. negative 4.66 2.68-8.08 0.0005 
Adjuvant Chemotherapy 
 
 
Non-platinum vs. platinum 
None vs. platinum 
 
1.43 
2.00 
 
0.99-2.08 
1.07-3.77 
 
0.059 
0.031 
 
Intense MMP-7 in cancer cells low vs. high 1.53 1.05-2.24 0.029 
RFS      
Residual tumor positive vs. negative 4.27 2.54-7.11 
 
0.0005 
Histological subtype serous vs. others 2.32 1.40-3.83 0.001 
Intense MMP-7 in cancer cells low vs. high 2.02 1.14-3.57 0.016 
RR= relative risk; CI= confidence interval 
 
Table 21. The independent prognostic factors of 10-year DRS (N=129) and RFS (N=72) by 
Cox multivariate analysis in the platinum-treated group. 
Variable Category RR 95%CI p-value 
DRS         
Residual tumor positive vs. negative 6.42 3.36-12.26 0.0005 
RFS      
Residual tumor positive vs. negative 5.10 2.35-11.09 0.0005 
RR= relative risk; CI= confidence interval  
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6. DISCUSSION 
6.1 Evaluation of the study material 
   The present retrospective study of 307 epithelial ovarian cancer patients was 
originally selected from a consecutive series of 445 women diagnosed and treated for 
ovarian malignancy [101]. The histopathological and clinical data used in the present 
study did not differ from that of the original group of patients (test of goodness for fit).  
In previous studies, the median age of patients at the diagnosis of epithelial ovarian 
cancer has been between 53 to 63 years [25][57], in line with the present study (62 
years). The distribution of the patients according to the histological grade, FIGO stage 
and histological subtype was similar to that described in many other studies 
[3][53][57][75][220]. The 5- year survival rates were congruent with those reported in 
earlier in each of the clinicopathological subgroup [57]. This suggests that there is no 
major selection bias in the present study material.  
However, because this study was done retrospectively, the treatment of the  patients 
was not standardized. Differences in the treatment of the study population can influence 
these kind of prognostic studies. The present material was collected during the years 
1976-1992 when currently used chemotherapy was still in it infancy. Previously 
radiation had been employed as an adjuvant to surgery in the management of selected 
stage I-III ovarian cancer patients [221-222]. A recent study has claimed that 
radiotherapy could improve patient survival in some specific subgroup of patients. 
However, treatment-related side effects seem to be frequent and limit the use of 
radiotherapy [56]. Currently, platinum-taxane-based chemotherapy is the recognized as 
the first line treatment of ovarian cancer [5][223]. In the 1980s, chemotherapy was the 
treatment of choice for the stage III-IV patients [222]. In the present study treatment 
choices were in line with the knowledge about adjuvant treatments available at that 
time, both in Finland and worldwide [221-222].  
The survival analyses on platinum treated population and the whole study material 
differed somewhat from each other (Tables 20 and 21). In the multivariate analyses, 
residual tumor was the only factor predicting DRS and RFS in both populations. 
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However, the study material in the platinum treated population was only half of the 
original material, and those patients had worse survival because of the higher stage and 
existence of the primary residual tumor, which may account for some of these 
differences. Lymph node assessments have been shown to be especially important in 
staging of early ovarian cancer to avoid understaging and potentially suboptimal 
treatment [53]. During 1972 –1992, surgical staging was not as efficient as today, since 
full lymphadenectomy was not systematically performed on all patients. This may have 
increased the number of stage I patients in the current study. However, the study by 
Westerlund and co-workers with fully surgical staged patients has reported even more 
stage I patients as compared to our patient cohort 36% vs. 27%. A recent nationwide 
study in Finland on the surgical treatment of ovarian cancer patients showed a similar 
frequency of stage I patients (28%) as the present study [53].  In the current study, 54% 
of the stage I patients were alive after 10 years follow-up, and 17% died for some other 
reason than ovarian cancer. This is in agreement with previously know survival rates for 
stage I patients [57][71], indicating that there was no any major distortion in our patient 
cohort. 
6.2 Evaluation of the study methods 
   In the present study the histological diagnosis of each patient was primarily assigned 
by 1-3 senior pathologists, after which an experienced pathologist re-evaluated all of the 
cases. This was done to decrease the observer-dependent bias in determining 
histopathological factors [224] and to confirm the original diagnosis.  
The tumor blocks were maintained at room temperature, which is the normal  practice 
in Finnish laboratories. The slides for this study were cut 2-3 months before staining 
and were stored at 4 ºC to avoid possible protein degradation. There were no significant 
differences in the quality of immunohistological staining results between the slides 
studied, excluding significant differences in handling and fixation methods, which has 
previously been shown to affect immunoreactivity [225]. Therefore, the quality of the 
stainings and specimens is sufficient to give reliable results. 
Before the staining, all the procedures were tested thoroughly since problems have 
been previously associated with immunohistochemical analyses [225-226], for instance, 
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different antibodies may give inconsistent results. For this reason CD44 and MMP-7 
were stained with two different antibodies. A good correlation between the staining 
results was observed (Kruskal-Wallis test and correlation coefficient), indicating data 
reliability. The specificity of each antibody was also confirmed using immonoblotting 
analyses, supporting the relevance of the immunohistochemical results. In all 
immunohistochemical and immunoblotting series, negative controls remained negative 
and all positive controls stained as expected.  Subjectivity in the interpretation was 
minimized by reviewing all samples at least 3 times and by at least 2 different observers 
(at least one of which was a senior pathologist).  
There have been no standardized criteria for scoring the immunohistochemical 
stainings in epithelial ovarian cancer [119][145][148-149][154][156]. A continuous 
scale (0-100%) was used in the present study. The percentage area of positive tumor 
cells from the total tumor cell area in each section was determined, excluding 
semiquantitatively samples with less than 300 tumor cells. For statistical analyses, the 
continuous variables were categorized into two groups based on the median value. The 
median value avoids introducing a bias that may be caused by the use of a minimum p-
value approach [227]. A median value is also easy to use. 
Tissue preparation is the cornerstone of immunohistochemistry. There is no universal 
fixative that is ideal for the demonstration of all antigens. However, there is a general 
consensus that paraffin sections produce satisfactory results for the demonstration of the 
majority of tissue antigens when supplemented with antigen retrieval techniques. 
Additionally, all of these antibodies are designed to be used on formalin-fixed paraffin-
embedded specimens. The expression of the studied markers was examined only by 
immunohistochemistry due to a lack of fresh tumor tissue from this patient cohort. 
Therefore we could not measure the activity of MMPs by zymography or quantitate the 
amount of protein for example, by ELISA. Indeed, it is known that the expressions of 
MMP-2 and MMP-9 are regulated at many levels, i.e. gene activation, mRNA stability, 
proenzyme activation, as well as by inactivation by endogenous inhibitors in a complex 
fashion by numerous oncogene and tumor suppressor pathways and conditions of 
hypoxia [228-229]. However, immunohistochemistry is a well established and widely 
used method in the evaluation of molecular marker expression in cancer research. 
 66 
 
 
   The reproducibility of immunohistochemistry has become important issue, since 
immunohistochemistry has developed from being only used in research to its current 
role as a major diagnostic tool in pathology [226]. However, as discussed above, many 
factors influence reproducibility; antibody, detection system, interpretation, cut-off 
levels, fixation, and tissue processing and it is very difficult to standardize all these 
factors [225-226][230]. Inter-laboratory reproducibility of immunohistrochemistry has 
been reported to be quite poor, however, inter-observer variation has been claimed to be 
of minor importance [231]. In the present study, about 10% of the samples in each study 
were stained twice. The results of these two different staining times were uniform 
showing good repeatability of the method.  
 
6.3 Clinicopathological prognostic factors in epithelial ovarian 
cancer 
   FIGO stage and size of the residual tumor have been the most consistent independent 
prognostic factors in epithelial ovarian cancer [224][232], which was confirmed also in 
the current study. In addition, histological grade, histological subtype and adjuvant 
chemotherapy were found to be independent predictors of patients survival in the 
present study, as also reported earlier [70][224][232-235]. Some studies have also 
shown that the patient’s age, ascites, and performance status are independent predictors 
of patients survival [61][64-67][69]. Ascites and performance status were not included 
into survival analyses in this study, whereas age was found to have prognostic 
significance for DRS in univariate analysis, but not in multivariate analysis. It is 
possible that other factors related to older age such as poor histological grade, advanced 
stage and more conservative treatment could explain why age is a significant predictor 
of patient survival in univariate but not in multivariate analyses [53].  
If the analysis was limited to those patients receiving platinum-based chemotherapy, 
the only independent predictor of DRS and RFS was the size of the residual tumor. It 
thus seems that residual disease is the most powerful indicator of survival supported 
recent findings by Wimberger and co workers [236]. It can be concluded that maximal 
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cytoreduction is one of the key elements for improving the survival of epithelial ovarian 
cancer patients. 
6.4 CD44 and HA in epithelial ovarian cancer 
   CD44 is a cell surface receptor with an important role in tumor cell invasion and 
metastasis. It is also a major cell surface receptor of HA [106]. It has been proposed that 
CD44 may have both tumor suppressing and promoting activity [237].  
   In the current study, CD44 was frequently detected on the surface of malignant tumors 
cells, while more rarely in normal epithelial cells, in line with previous publications on 
epithelial ovarian cancer [21][113][115][119]. No changes in CD44 expressions during 
metastasis were found in the present study, a finding supported by the results of Berner 
and co-workers [118]. However, there are also reports suggesting down-regulation of 
CD44 during tumor progression [117][119][238], and studies showing more frequent 
expression of CD44 in borderline tumors, as compared to benign and malignant tumors 
[115-116]. Nonetheless, since normal ovarian epithelial cells only rarely express CD44 
[113][119], it can be concluded that CD44 seems to be related to the initiation of the 
proliferative or neoplastic processes [113], or that enhanced CD44 expression may 
reflect the activation state of the cell in which the neoplastic event occurred [239]. This 
could explain the variable results between different tumor samples, stressing the role of 
CD44 during cancer initiation rather than later progression.  
   In the metastasis of epithelial ovarian cancer, the key elements are binding of cancer 
cells to the peritoneal mesothelium and migration towards the underlying extracellular 
matrix. It has been shown that CD44 with its interaction to HA can regulate these 
processes [16][21-22]. However, the present results do not support the theory that CD44 
is important in mediating tumor spreading in epithelial ovarian cancer [21- 22]. On the 
contrary, CD44 was shown to be present in well-differentiated and less aggressive 
histological subtypes of ovarian tumors. It has been reported that the ovarian carcinoma 
cells can use several molecular mechanisms such as intergrins, CD44 and cell surface 
lectins to adhere to the complex extracellular matrix of the peritoneum [109]. Based on 
the present study, these other molecules, rather than CD44, are important in the 
peritoneal spreading of epithelial ovarian cancer. In addition, the present study revealed 
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a positive correlation between the levels of CD44 and HA in cancer cells in the primary 
tumors, a finding in line with the HA receptor function of CD44. However, this could 
not be seen in the metastasized tumor which may be explained by the low number of 
available samples. This lack of correlation between HA and CD44 in the tumor 
metastasis may reflect changes that can occur in the HA receptor function of CD44 
[237][239]. 
   The prognostic role of CD44 has been controversial in epithelial ovarian cancer 
(Table 22). In this study, CD44 was associated with a favorable prognosis, which is 
supported by two previous studies [113][117], while two reports have shown opposite 
findings [114][116]. In addition, no association has been seen in a number of studies 
[111][115][118-120]. The most probable reasons for these differences are discussed in 
the last paragraph of the Discussion section.  
   To conclude, while stromal HA correlates with poor survival of the patients [101], 
cancer cell-associated CD44 expression is a positive prognostic indicator in epithelial 
ovarian cancer and associates with a mucinous histological subtype and with low 
histological grade of the tumor. However, the results should be further confirmed in a 
large, prospectively study. It is also necessary that possible differences in antibodies are 
controlled before they are used in CD44 detection in epithelial ovarian cancer.  
6.5 Matrix metalloproteinases and EMMPRIN in epithelial 
ovarian cancer 
6.5.1 Expression of MMPs and EMMPRIN  
   Matrix metalloproteinases are a family of zinc-dependent endopeptidases capable of 
degrading any extracellular matrix component. They have also a critical role in tumor 
progression [15][17]. The present study confirmed that normal and benign ovarian 
samples and malignant tumors are positive for MMP-2 and –9 in both epithelial cells 
and the stromal area [148-149][151-152][155-160][240]. Unlike other MMPs which are 
found both in tumor and stromal cells, the expression of MMP-7 occurs mainly in 
ovarian tumor cells [147][162-163]. As in previous studies [145-146], MMP-7 
expression was found in cancer cells in the present study, while a weak stromal MMP-7 
staining was also present.  
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   In the current study, EMMPRIN, an inducer of various MMPs, was expressed in the 
epithelium of normal ovary and benign tumors. In the malignant lesions, staining was 
seen mainly on the cancer cell membrane, but also to some extent in the tumor cell 
cytoplasm and peritumoral stroma,  in agreement with earlier studies on ovarian cancer 
and different other tumors [183][186][241-242]. The present and a previous study on 
ovarian samples [241] showed more membranous than cytoplasmic expression of 
EMMPRIN with no marked increase in malignant cells. However, there are also reports 
suggesting that EMMPRIN is expressed significantly more often in malignant tumors 
than in their non-malignant counterparts [183][187][189][242]. The discrepancies may 
result from the different study materials, methods, and antibodies used in the different 
series. Scoring methods may also contribute to the differences in the results [187][242].  
6.5.2 Relation of MMPs and EMMPRIN to clinicopathological factors 
   In the present study, low cancer cell-associated MMP-7 and -9 expressions correlated 
with advanced stage tumors. In addition, low cancer cell-associated MMP-2, -7 and -9 
expressions were significantly associated with large residual tumor and poor 
histological differentiation. A correlation to histological grade has been previously 
reported for intense MMP-2 in ovarian cancer cells [171]. A low cancer cell-associated 
MMP-9 expression correlated also with the clear cell histological subtype in the current 
study. No significant correlations of MMP-9 with the traditional clinicopathological 
factors have been shown in ovarian cancer[152][154][156]. In the present study, a low 
EMMPRIN expression on cancer cell membrane was associated with a large primary 
residual tumor, a advanced stage of the tumor and was detected more often in serous 
adenocarcinomas than in other subtypes. These results are in agreement with previous 
findings in ovarian cancer and on melanoma [241][243]. However, contradictory results 
have been published in ovarian serous adenocarcinoma [242]. Differences in 
EMMPRIN staining also exist between histological types of benign tumors. The loss of 
membranous EMMPRIN might be a very early step in the progression of serous 
cystadenomas towards the corresponding malignancy.  
   In the current study, high stromal MMP-9 expression associated significantly with 
advanced stage of the tumor. Elevated stromal MMP-2 levels were frequently associated 
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with advanced stage of the tumors and a large residual tumor. However, these results 
did not reach statistical significance. According to the study by Kamat and co-workers, 
stromal MMP-9 correlated with advanced stage, high grade, ascites, serous histological 
type, suboptimal cytoreduction, and lymph node positive disease [169]. Both stromal 
MMP-2 positivity [160][169] and negativity [155] have been correlated with higher 
histological grade, advanced stage and disease recurrence of ovarian cancer. In the 
current study, the pattern of MMP-9 expression (cellular vs. stromal) is likely to be a 
reflection of the grade or the stage of the tumor. The metastatic lesions showed 
increased stromal MMP-9, which supports the role of stromal MMP-9 in the 
progression of ovarian cancer.  
6.5.3 Relationship of studied markers to each other 
   This is the first report evaluating the relationship between gelatin binding MMPs and 
HA/CD44, as well EMMPRIN and HA/CD44 in epithelial ovarian cancer.  It has been 
suggested that HA promotes cancer cell invasion by regulating the production, 
activation and cell-surface expression of MMPs [91-94]. Cell-associated MMP-2 and –9 
expressions correlated inversely with cell associated HA, whereas both stromal MMP-2 
and -9 expressions were positively correlated with stromal HA expression. According to 
the current study, HA may activate MMP-2 and -9 in tumor stroma, and they can act 
together to promote the progression of ovarian cancer. This finding gives further 
support for the concept of tumor stroma being a therapeutic target in epithelial ovarian 
cancer. Elevated EMMPRIN expression in tumor cells has been shown to stimulate HA 
production in these cells, probably due to elevated expression of HA synthases [182]. 
Additionally, EMMPRIN has been shown to increase drug resistance via HA [244]. 
However, in the present study no significant correlation existed between EMMPRIN 
and HA expressions in ovarian cancer.  
CD44 may anchor proteolytically active MMP-9 to the tumor cell surface and may 
therefore promote CD44-mediated invasion [110]. In the present study, no correlation 
was found between epithelial CD44 and MMP-9 expressions, whereas strong MMP-2 
expression in cancer cells was found to correlate weakly with that of CD44 in cancer 
cells. It has been reported that in human melanoma cells [92] and lung carcinoma cells 
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[94] CD44 may promote tumor progression by enhancing MMP-2 secretion. The results 
of present study suggest that CD44 may have some role in promoting MMP-2 secretion 
also in epithelial ovarian cancer. In gastric carcinoma, the expression of MMP-7 
correlates positively with the expression of CD44v6 protein, which supports the 
hypothesis that MMPs can modulate cell adhesion [245]. CD44 can mediate docking of 
active MMP-7, and help to control physiological tissue remodelling and prevent 
inappropriate ECM degradation [246]. The findings of the present study support the link 
between MMP-7 and CD44. We have described for the first time that the level of MMP-
7 expression in ovarian cancer cells correlates weakly but significantly with CD44 
expression. The cell surface CD44 has shown to be shed by MT1-MMP, and this 
interaction seems to stimulate cell migration [247]. Tumor-derived MT1-MMPs have 
suggest to play a critical role also in tumor invasion and proliferation by activation of 
pro-MMP-2 [132][248]. It has also an important role in the transition of cells from 
normality to malignancy [249-250]. These findings are interesting; however, the present 
study did not investigate the expression of MT1-MMP. 
Mutated β-catenin, located in cell nucleus, is involved in the Wnt signaling pathway 
[193]. Mutations of β-catenin are characteristic of the endometrioid type of ovarian 
carcinomas [201-203]. In the present study, a high percentage of MMP-7, intense 
MMP-7, and CD44 expression in cancer cells were significantly associated with nuclear 
positivity of β-catenin in endometrioid cancers. This result is in line with the finding 
suggesting that binding to the transcription factor TCF, mutated β-catenin can increase 
the expression of MMP-7 and CD44 [129-130][200]. In addition, in this study a high 
percentage of MMP-7 and intense MMP-7 expression in cancer cells correlated with 
strong cytoplasmic positivity for β-catenin, especially in endometrioid and clear cell 
subtypes. These results support the theory that before translocation to the nucleus, 
mutated β-catenin can accumulate in cell cytoplasm by avoiding degradation [199].  
6.5.4 Prognostic value of MMPs and EMMPRIN 
   In the current multivariate analyses, strong MMP-2 and -7 expressions in cancer cells 
were independent prognostic factors for better DRS, and MMP-7 also for RFS. In 
addition, in FIGO stage I patients, MMP-9 expression in cancer cells associated with 
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better survival. Similar results have been published by Ozalp and co-workers [154]. The 
prognostic significance of MMP-2 and –9 has been studied only in a few studies, and 
the results of these studies have been conflicting [148-149][155][160][169], see Table 
22. As far as we are aware, no previous publications deal with the prognostic 
significance of cancer cell associated EMMPRIN in epithelial ovarian cancer. In this 
study, a low membranous EMMPRIN expression was an independent predictor for poor 
DRS in the high grade tumors. Positive or high EMMPRIN staining in cancer cells has 
been shown to associate with poor survival in some tumor types [187][190-191], 
whereas others have shown no prognostic significance of cancer cell associated 
EMMPRIN [192]. Differences of the prognostic role of MMPs and EMMPRIN are 
discussed in more detail in the last paragraph of the discussion. 
In the present study, stromal MMP-9 expression predicted poor survival, and stromal 
MMP-2 also showed a trend towards reduced DRS. In addition, positivity of stromal 
MMP-7 predicted poor RFS, a completely novel result. These findings highlight the 
importance of tumor stroma in the biological behavior of ovarian cancer and concur 
with the recent findings, indicating that in a univariate analysis, high stromal expression 
of MMP-2 and -9 is associated with short survival of the patients [169]. In other 
cancers, stromal MMP-2 and -9 expressions have also been found to predict poor 
survival [166][251]. Davidson and co-workers have reported that the expression of 
EMMPRIN in stromal cells correlates with poor survival in serous ovarian carcinoma 
[186]. This is in contrast to our results indicating that stromal EMMPRIN seems to have 
no prognostic significance in ovarian cancer.  
6.6. Prognostic significance of cell-associated CD44, MMPs and 
EMMPRIN compared with earlier published data  
   Findings of the current study on the prognostic significance of cancer-cell associated 
CD44, MMPs and EMMPRIN were partly different from those published earlier by 
other groups [164][187][190-191]. The discrepancies can be explained by differences in 
the study methods, including the antibodies, and study material, i.e. differences in the 
treatments and patient populations [148-149][155][160]. Some of these factors have 
already been discussed in paragraphs 6.1 and 6.2. 
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   The fraction of serous type cancers has ranged from 36% to 68% in different studies 
[114][119][169]. In addition, some studies include only some of the histological 
subtypes i.e serous and endometrioid histological subtypes [160][186], and are therefore 
not comparable to this study which included all histological subtypes. Serous tumors 
have a low survival rate as compared to other histological subtypes [57][76], and  
therefore influence the survival rate. Similarly, the percentage of advanced stage tumors 
(FIGO stage III-IV) has varied in different studies from 84% to 59%, 
[53][116][155][169]. Patients with FIGO stage I-II have a significantly better survival 
rate compared to those with stage III –IV disease [57][71], thus the distribution of early 
and advanced stage tumors influences the outcome of the study population. All of the 
above studies with discordant results have significantly smaller patient cohorts than the 
present study, see Table 22. In future, larger and more uniform patient cohorts will be 
needed to evaluate in detail the prognostic role of the studied biological markers.  
   Recent studies on different cancers using either different [165][167-168][252]  or  the 
same antibodies as in the present study [100][166][253-254] have shown that expression 
of cancer cell-associated CD44, MMP-2, -7 and -9 are predictors for favorable survival. 
These results are in line with the present study. However, other studies in certain 
cancers, conducted with the antibodies different from ours have revealed  that the 
epithelial expressions of EMMPRIN and MMP-2, -7 and -9 are independently related to 
poor prognosis [187][190-191][255-260]. The association of CD44, MMPs and 
EMMPRIN to the clinical outcome is thus specific for each tissue and tumor type. The 
role of CD44, MMPs and EMMPRIN can be also quite variable in different cancers, 
and also for specific stages of the cancer which undoubtedly explain some of the 
differences. 
   MMPs are secreted as inactive enzymes which are later activated in the extracellular 
milieu. It has been suggested that only the activated protein is biologically or 
pathologically relevant, not the expression of protein as such [261]. Proteolytic activity 
has been generally detected in the stromal compartment of the malignant tumors 
[19][161]. The present study was conducted using an antibody that recognizes both the 
pro- and active form of the MMP-2 and 9 proteins. Both pro- and active MMP-9 
enzymes have been reported to be useful markers of survival in epithelial ovarian cancer 
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[152][262]. A study by Wu and co-workers indicates that active MMP-2, but not pro-
MMP-2, represents potential marker to predict patient outcome [156]. It may be that 
inactive enzymes reside in tumor cells while active enzymes exist in the stroma [165]. 
Further works should be done using antibodies that separately recognize the pro- and 
active forms of these proteins, and more importantly, a method is needed to measure 
their actual activity in fresh tumor material. 
   Based on the knowledge that the majority of MMPs have an adverse effect on patient 
survival, a broad spectrum of MMP inhibitors have been tested in the treatment of 
cancers. However, the results of these new treatments have been rather disappointing 
[17]. During the last few years it has became clear that the role of  MMPs  in tumor 
progression is much more complex than simply cleavage of the basement membrane to 
facilitate invasion into the surrounding connective tissue and blood vessels [263-264]. A 
number of new targets for MMPs have been discovered, including growth factors, 
growth factor receptors, cell-associated molecules, and cytokines [263].  
   MMPs play a complex role in tumor progression [263-264]. As a result of having the 
variable targets, MMPs may participate also in tumor-suppression [263]. Based on our 
results it can be concluded that MMP-2, -7 and -9 have a dual prognostic significance in 
epithelial ovarian cancer depending on the site of MMP localization. The higher the 
amount of cancer cell associated MMP, the better the survival, whereas the higher the 
stromal expression of MMP, the poorer the survival. EMMPRIN has a similar 
prognostic significance, acting against tumor advancement when it is present in the 
tumor epithelium. Mice without a functional MMP-9 gene have less peritoneal tumors, 
ascites and angiogenic activity following implantation of human ovarian cancer cells, as 
compared to mice with an intact MMP-9 gene [85]. These findings lead to the 
suggestion that tumor stroma may be a therapeutic target in ovarian cancer [265]. 
Tumor cells stimulate the expression of MMPs in their surrounding environment [19]. 
Therefore, attempting to interfere with the interaction between the tumor and its stroma 
would also represent a good therapeutic target [265].  However, further work is required 
to clarify the significance of MMPs and EMMPRIN in the progression of epithelial 
ovarian cancer. Intense MMP-7 staining seems to be the most promising new prognostic 
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marker for patient survival, even though it did not prove to be more powerful than the 
standard prognostic factors. 
 
Table 22. Prognostic studies in ovarian cancer using immunohistochemical methods on 
each of the studied molecules  
  Author (ref nro) 
Patient N 
(malignant) Prognosis 
CD44 Sillanpää et al.  307 good RFS (MV) 
 Kayastha et al.[114] 56 poor DFS (MV) 
 Ross et al. [117] 64 good survival (UV) 
 
Rodriquez-Rodriques et al. 
[113] 
142 
 
good survival (MV) 
 
 Cho et al. [116] 95 poor DFS (MV) 
 Cannistra et al. [111] 31 ns 
 Saegusa et al. [119] 115 ns 
 Berner et al. [118] 67 ns 
 Schroder  et al.[120] 50 ns 
  Zagorianakou et al.[115] 83 ns 
MMP-2 De Nictolis et al.[148] 18 ns 
 
Sillanpää et al. 
 
295 
 
strong in cancer cells:  good DRS 
(MV) 
 
Garzetti et al.[149] 21 cancer cells:  short DFS (MV) 
 
Westerlund et al.[155] 
 
33 
 
stroma:  long DRS (UV)         
cancer cells:  short DRS (UV) 
  
Torgn et al.[160] 84 Stromal: poor DFS and RFS (UV) 
MMP-2 and 
-9 
 
Kamat et al.[169] 
 
 
90 
 
 
epithelial and stromal  MMP-2 and –
9:  short DSS (UV), stromal MMP-9:  
poor DSS (MV) 
MMP-9 
 
Sillanpää et al.  
 
292 
 
cancer cells:  good DRS (UV) 
stromal:  poor DRS (UV) 
  
Ozalp et al  [154] 
 
30 
 
cancer cells:  tendency to long OS 
(MV), stromal:  short OS (MV) 
EMMPRIN Davidson et al  [186] 55 stromal:  poor survival (UV) 
  Sillanpää et al. (submitted) 295 cell membrane:  good DRS (UV) 
MMP-7 
 
Sillanpää et al.  
 
284 
 
intense cancer cells: good DRS (MV) 
stromal:  poor RFS (UV) 
UV= univariate survival analysis, MV= multivariate survival analysis, RFS= relapse-free 
survival, DFS= disease-free survival, DRS= disease related survival, DSS= disease specific 
survival, OS= overall survival, ns= non significant 
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7. SUMMARY AND CONCLUSIONS 
 
   The results of the current study show that 
 
1. The relatively abundant expression of CD44 in epithelial ovarian cancer cells was 
significantly related to other clinicopathological factors of better survival. CD44 in 
cancer cells was found to indicate independently a favorable RFS in epithelial ovarian 
cancer. 
 
 2. Cancer cell-associated MMP-7 expression was found to correlate significantly with 
other clinicopathological factors known to be associated with better survival.  Intense 
cancer cell associated MMP-7 was an independent prognostic factor of better DRS and 
RFS in epithelial ovarian cancer.  
 
3. Nuclear beta-catenin, especially in endometrioid tumors, was associated with MMP-7 
and CD44 expression in cancer cells. Nuclear β-catenin expression also predicted better 
DRS in the subgroup of patients with endometrioid ovarian cancer. 
 
4. The role of MMP-9 in tumor progression is dependent on tissue location. It acts 
against tumor advancement when expressed in the tumor epithelium but promotes tumor 
progression while in the stroma. High MMP-9 expression in carcinoma cells predicted a 
better DRS, whereas high stromal MMP-9 predicted a poor DRS. Neither of these 
factors were independent prognostic factors for survival. 
 
5. Membranous EMMPRIN, and cancer cell associated MMP-2 were markers for better 
DRS. In addition, strong MMP-2 expression in cancer cells was an independent 
prognostic factor for better DRS.  
 
6. Stromal MMP-2 and –9 expressions were associated with stromal HA expression, 
and they may interact in the progression of ovarian cancer. 
 77 
 
 
On the basis of this study, cancer cell-associated MMP-2 and –7, and CD44 along 
with the conventional clinicopathological factors such as FIGO stage, residual tumor, 
and histological type and grade, adjuvant chemotherapy, are independent 
prognosticators in epithelial ovarian cancer. However, the conventional 
clinicopathological factors seem to be the most powerful prognosticators. Of the studied 
molecules, intense MMP-7 seems to be the most promising factor since it retained its 
prognostic significance in both DRS and RFS analyses when all the independent factors 
were included. Clarifying the importance of the studied biological markers is crucial if 
we wish to unravel the molecular mechanisms in the progression of epithelial ovarian 
cancer. 
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